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CHAPTER 1 
 
INTRODUCTION 
 
Epidemiology of lung cancer 
Incidence 
Cancer is a major public health burden worldwide, with 14.1 million new cases 
diagnosed in 2012 and is expected to increase in number to an estimated 20 million new 
diagnoses yearly by 2030 (Stewart et al. 2014).  Globally, lung cancer accounts for 
approximately 13% of all cancer cases (Ferlay et al. 2010, Stewart et al. 2014). In females alone, 
lung cancer is the third leading cause of cancer worldwide (8.7% of cancer cases) behind breast 
and colorectal cancers (25.2% and 9.2%, respectively), while it remains the leading cause of 
cancer in men (16.7%), followed closely by prostate cancer (15.0%) (Stewart et al. 2014).  
In the United States, lung cancer is responsible for 13% of all new cancer cases (Figure 
1), second only to prostate cancer incidence in men and breast cancer in women (American 
Cancer Society 2017). Cumulatively, men and women have a 6-7% probability of being 
diagnosed with lung cancer during their lifetime, with greater risk at increasing ages (American 
Cancer Society 2017). Specifically, 16.4 in 100,000 individuals under the age of 65 are 
diagnosed with lung cancer, compared to 327.9 in 100,000 individuals above 65 years of age 
(Howlader N). The majority (57%) of lung cancer cases are diagnosed at distant stage disease; 
regional and localized disease diagnoses account for 22% and 16% of cases, respectively (Figure 
2) (Siegel et al. 2017). 
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Lung cancer incidence rates also differ by race ethnicity, with more black/African 
American cases occurring than any other race/ethnicity (Howlader N , American Cancer Society 
2017). Specifically, the North American Association of Central Cancer Registries reported 77.7 
in 100,000 white male cases in 2009-2013 verses 90.8 in 100,000 black male cases during the 
same time (American Cancer Society 2017). The number of female lung cancer cases is slightly 
higher in whites compared to blacks, with 58.2 and 51.0 in 100,000 lung cancer cases in 2009-
2013, respectively (Howlader N , American Cancer Society 2017). While overall incidence rates 
are similar for black and white individuals (males and females combined) over the age of 65 
(341.0 vs. 339.9 per 100,000, respectively), blacks, particularly black males, are diagnosed at 
younger ages compared to whites (Figure 3) (Howlader N). Furthermore, blacks are more 
commonly diagnosed at distant stage disease (61% vs. 56%) and less commonly diagnosed at 
localized stage disease (13% vs. 16%) compared to whites (Figure 2) (Howlader N , Siegel et al. 
2017).  
Surveillance, Epidemiology, and End Results (SEER) Program data show lung cancer 
incidence rates peaked for all races in 1992, and have been declining ever since (Howlader N). 
However, it is important to note that incidence rates have peaked separately for males and 
females, in large part due to differing smoking habits between the sexes, which will be discussed 
later in this chapter. For black males, incidence rates were highest in 1984 at 158.8 per 100,000 
individuals, while rates among black females did not peak until 2002, with 60.6 per 100,000 
individuals (Figure 4) (Howlader N). Similarly, incidence rates for white males peaked in 1987 
(100.7 per 100,000), nearly 20 years before white females in 2007 (56.0 per 100,000, Figure 4) 
(Howlader N). 
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Mortality 
 Worldwide, cancer accounted for 8.2 million deaths in 2012, with approximately 13% of 
those deaths attributable to lung cancer, making lung cancer the leading cause of cancer-related 
death across the world (Ferlay et al. 2010, Stewart et al. 2014). Within the United States, 155,870 
lung cancer death are estimated for 2017, which translates to 26.6% of cancer-related deaths in 
males and 25.2% of cancer-related deaths in females (American Cancer Society 2017). Lung 
cancer accounts for more deaths than the next three leading cancers combined (Figure 1), which 
can largely be attributed to the high number of distant stage diagnoses (Howlader N , American 
Cancer Society 2017). Only 4% of individuals diagnosed with distant stage disease survive 5 
years (Howlader N , American Cancer Society 2017). Survival rates increase with earlier stage 
diagnosis: individuals diagnosed at regional stage disease have a 28% 5-year survival rate and 
individuals diagnosed with localized disease have 55% 5-year survival rates (Howlader N , 
American Cancer Society 2017). 
 While 5-year mortality rates have increased in recent years, blacks have consistently had 
poorer survival compared to whites (16% vs. 19% 5-year survival rates, respectively). (Howlader 
N , American Cancer Society 2017). Death rates for black and white males peaked in 1990 
(125.2 and 86.0 per 100,000, respectively) and have steadily declined since then (Figure 5) 
(Howlader N). In 2014, the most recent year of SEER data, male death rates were 62.5 and 52.1 
per 100,000 for blacks and whites, respectively (Howlader N). In females, death rates did not 
begin to decline until nearly 10 years after males, a trend similar to female incidence rates 
(Figure 5). 
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Lung cancer histology 
 The two most frequent histological types of lung cancer are non-small cell and small cell. 
Non-small cell lung cancer cases can be further divided into multiple subtypes, the most 
common being adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. The 
following sections will discuss common characteristics and epidemiologic patterns of the four 
main lung cancer subtypes. 
 
Non-small cell lung cancer 
 Non-small cell lung cancer comprises 84% of all lung cancer diagnoses, of which 
adenocarcinoma accounts for almost half (46.6% of all lung cancer cases) (Howlader N). 
Squamous cell and large cell carcinomas account for 23.2% and 1.6% of lung cancers, 
respectively (Table 1). There is relatively little difference in the distribution of histologic 
subtypes between blacks and whites (Howlader N). There are, however, differences in subtype 
presentation between males and females: a greater percentage of females (51% compared to 43% 
of males) are diagnosed with adenocarcinoma, while a greater percentage of males (28% 
compared to 18% of females) are diagnosed with squamous cell carcinoma (Howlader N). While 
adenocarcinoma is the most common lung cancer histologic type in men and women, it has only 
risen to that position in recent years; until the early 1990s squamous cell carcinoma was the most 
common lung cancer subtype, accounting for nearly 50% of lung cancers in males in 1973 
(Devesa et al. 2005, Meza et al. 2015). Interestingly, squamous cell carcinoma is more 
commonly associated with smoking-related lung cancers, while adenocarcinoma includes more 
never-smoking lung cancer cases than any other histologic subtype (William D. Travis 2004, 
Stewart et al. 2014). 
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 Distinct morphologic and histologic characteristics separate non-small cell lung cancer 
subtypes. Lung adenocarcinomas, for example, are most commonly diagnosed in the peripheral 
lung, while most squamous cell carcinomas are centralized (though the proportion of periphery 
tumors is growing) (Stewart et al. 2014). Morphologically, adenocarcinomas are glandular with 
acinar, papillary, bronchioloalveolar or solid with mucin growth patterns (William D. Travis 
2004, Stewart et al. 2014). By contrast, squamous cell carcinomas display intercellular bridges 
arising from the bronchial epithelium and keratinization (William D. Travis 2004, Stewart et al. 
2014). Large cell carcinoma is histologically diagnosed through the exclusion of granular or 
squamous cell carcinoma (William D. Travis 2004, Stewart et al. 2014). Non-small cell lung 
cancers also differentiate by genetic mutation profiles. 
 While most non-small cell lung cancers are diagnosed at late stage disease, there is some 
variation among subtypes. Specifically, squamous cell carcinoma tends to be diagnosed at earlier 
disease stages compared to adenocarcinomas and large cell carcinomas (Table 1) (William D. 
Travis 2004). Five-year relative survival rates for localized, regional, and distant non-small cell 
lung cancer are 59.5%, 32.3%, and 5.2%, respectively (Howlader N). However, these rates differ 
between blacks and whites in both sexes and across all stages, with only 17.5% of black non-
small cell lung cancer cases (all stages) surviving 5 years compared to 22.6% percent of whites 
(Howlader N). 
 
Small cell lung cancer 
 Small cell carcinoma accounts for 15% of all lung cancers and typically occurs in heavy 
smokers (Howlader N , William D. Travis 2004, Stewart et al. 2014). Morphologically, small 
cell lung cancer is defined by small round, oval or spindle shaped cells, with scant cytoplasm, 
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granular chromatin, and absent or inconspicuous nucleoli (William D. Travis 2004, Stewart et al. 
2014). Seventy-four percent of small cell lung cancers occur in a centralized location within the 
lung (William D. Travis 2004).  
 The relative proportion of small cell lung cancer cases has remained steady over time 
(Meza et al. 2015). The overall 5-year relative survival rate for small cell lung cancer (all stages, 
all races) is substantially reduced compared to non-small cell lung cancers (6.5%, vs. 22.1%, 
respectively) (Howlader N). The majority (53%) of small cell lung cancers are diagnosed at 
distant stage disease (Table 1), which is associated with a 2.9% 5-year relative survival rate 
(Howlader N , William D. Travis 2004). Regionally staged disease, which accounts for 26% of 
small cell lung cancers, and locally staged disease, which accounts for 8% of small cell lung 
cancers (Table 1), have 5-year survival rates of 15.3% and 28.9%, respectively (Howlader N , 
William D. Travis 2004). There is little difference between stage distributions between blacks 
and whites, though a slightly greater proportion of females are diagnosed at regional stage 
disease compared to males (22% vs. 18%, respectively), which in turn gives females slightly 
better 5-year survival rates (7.8% vs. 5.2% for all stages combined, respectively) (Howlader N).  
 
Risk Factors 
Smoking 
 Smoking is by far the greatest risk factor for lung cancer, accounting for 80-90% of all 
lung cancer cases (Centers for Disease Control and Prevention , American Cancer Society 2017). 
Some of the first evidence for an association between tobacco smoking and lung cancer came in 
1950 when Wynder et al. examined a population of 684 confirmed lung cancer cases, of which 
95% were heavy smokers compared to 75% of controls (Wynder and Graham 1950). Similarly, 
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Doll and Hill (1950) observed significantly increased smoking rates and quantities among lung 
cancer cases in central London. However, it wasn’t until the release of the Surgeon General’s 
report on smoking and health in 1964 (Wellmann 1964) that widespread tobacco control 
measures began, resulting in a dramatic decrease in tobacco consumption. In fact, it is estimated 
that tobacco consumption would be more than 370% higher than it is today in the absence of the 
surgeon general’s report and the resulting tobacco control efforts (Warner et al. 2014). Similarly, 
Holford et al. estimate that approximately 60% of males and 45% of females would be current 
smokers today without these counter tobacco efforts (compared to the approximately 25% and 
20% actual current smokers today, respectively), and as a result more than 8 million lives have 
been saved from smoking-related deaths (Holford et al. 2014). With specific regard to lung 
cancer, approximately 800,000 lung cancer related deaths were avoided due to tobacco control 
efforts and another 1.7 million could have been avoided had control efforts resulted in complete 
smoking cessation in 1965 (Moolgavkar et al. 2012).  
 The increase in tobacco control efforts has undoubtedly contributed to the observed 
changes in histological prevalence over time. As stated previously, squamous cell carcinomas are 
predominantly observed in ever smokers, while adenocarcinomas are observed more frequently 
in never smokers (William D. Travis 2004, Stewart et al. 2014). As tobacco cessation efforts 
have increased, the frequency of squamous cell carcinoma diagnoses has decreased, while 
adenocarcinoma diagnoses have increased (Meza et al. 2015).   
 Historical differences in smoking habits and behaviors between men and women have 
also influenced lung cancer trends. Examination of SEER data from 1975-2014, reveals that 
incidence rates among men began declining nearly 20 years earlier than in women (Howlader N , 
Siegel et al. 2017). Similarly, women were also approximately 20 years delayed in smoking 
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initiation and began smoking at much older ages compared to men (Harris 1983, Shopland 1995, 
Moolgavkar et al. 2012). Furthermore, smoking cessation rates have declined much more rapidly 
among men than among women (Shopland 1995, Moolgavkar et al. 2012).  
 
Occupational and environmental exposures 
 While smoking is by far the strongest risk factor for lung cancer, occupational and 
environmental exposures account for a substantial number of lung cancer cases. A list of 
common exposures is provided in Table 2. Below I will describe a few examples of such 
exposures.  
Ionizing radiation (e.g. gamma-rays, x-rays, and alpha-particles such as radon and 
plutonium) is a group 1 carcinogen as classified by the International Agency for Research on 
Cancer (IARC), meaning it is a known human carcinogen (Field and Withers 2012). Exposure to 
x-rays and gamma-rays occurs primarily in the medical industry, while plutonium exposure 
occurs in occupations related to nuclear weapon or nuclear power production (William D. Travis 
2004, Field and Withers 2012). Radon is perhaps one of the oldest known occupational lung 
carcinogen and most commonly affects miners, though radon exposure can occur in other 
environments (William D. Travis 2004, Samet et al. 2009, Field and Withers 2012). Among the 
first evidence of the association between radon and its decay products was observed in a 
population of Navajo uranium miners (Samet et al. 1984, Roscoe et al. 1995). Within a non-
smoking mining population, the lung cancer mortality ratio was 12.7 (8.0-20.1), indicating a 
strong association between radon exposure and lung cancer even in the absence of tobacco 
exposure (Roscoe et al. 1989). A causal link between radon exposure and lung cancer in miners 
has been confirmed in numerous studies (1999, Schubauer-Berigan et al. 2009, Lane et al. 2010). 
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 Another commonly cited occupational exposure is asbestos, a fibrous silicate material. 
Asbestos possesses many desirable qualities that made it a product commonly used in industry, 
such as heat stability, thermal and electrical insulation, and resistance to degradation (National 
Toxicology Program). At the peak of asbestos consumption, the primary uses for it included 
cement pipes, flooring, roofing, and automobile brakes and clutches, though production of 
asbestos-containing products has drastically decreased since it was associated with increased 
lung cancer risk, particularly among smokers (National Toxicology Program , Selikoff et al. 
1968). According to a population-based study of lung cancer risk in Sweden, the relative risk for 
lung cancer with asbestos exposure is 1.68 (95% Confidence Interval (CI): 1.15-2.46) 
(Gustavsson et al. 2000). While a nearly two-fold increased risk of death was observed among 
asbestos textile workers compared to non-asbestos exposed textile workers (Loomis et al. 2009), 
with similar observations across several studies (Loomis et al. 2010, Elliott et al. 2012, Loomis 
et al. 2012).  
 Several of the occupational exposures listed in Table 2 are also classified as 
environmental exposures. While individuals working in such industries are undoubtedly exposed 
to higher concentrations of the carcinogenic compound, risk still remains for individuals in the 
general population as particulates are released into the air. For example, diesel exhaust is 
classified as an IARC group 1 known carcinogen and is associated with lung cancer risk (Attfield 
et al. 2012, Garshick et al. 2012, Silverman et al. 2012, Silverman 2017); while truckers, miners, 
and other related occupations are at higher risk given their repeated exposures (Pronk et al. 2009, 
Attfield et al. 2012, Silverman et al. 2012), the release of diesel exhaust into the air also acts as 
an environmental exposure to the general population. 
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Chronic Obstructive Pulmonary Disease 
 Chronic obstructive pulmonary disease (COPD) describes a group of lung diseases 
including emphysema and chronic bronchitis and is diagnosed through measures of lung function 
such as forced expiratory volume in one second (FEV1). Like lung cancer, one of the most 
common risk factors for COPD is tobacco smoking. Approximately 40-70% of lung cancer 
patients also have COPD and several studies have noted a strong association between lung 
cancer and COPD (Wasswa-Kintu et al. 2005, Dela Cruz et al. 2011, Houghton 2013). 
Specifically, a meta-analysis of 39 studies reported a relative risk for lung cancer of 1.80 (95% 
CI: 1.60-2.11) for individuals with a previous diagnosis of COPD, emphysema, or chronic 
bronchitis (Brenner et al. 2011) and results from the National Lung Cancer Screening Trial 
(NLST) show a 2-fold increased risk for lung cancer among individuals with confirmed COPD 
(Young et al. 2015). Other studies have suggested that a COPD diagnosis may also be associated 
with certain histologic subtypes (Papi et al. 2004, Young et al. 2015). Despite clear evidence of 
an association between lung cancer and COPD, the causal relationship between the two diseases 
remains poorly understood (Houghton 2013). Given the increased risk for both diseases imposed 
by smoking, several have suggested a connection simply through shared etiologic pathways 
(Houghton 2013). However, in a Caucasian population of ever smokers, the prevalence of COPD 
was six times greater among lung cancer cases compared to controls matched on smoking status, 
age, and sex, suggesting COPD alone is a risk factor for lung cancer (Young et al. 2009). 
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Genetic contributions to lung cancer 
Somatic mutations 
 Somatic mutations in tumor cells have been heavily studied in lung cancer. Across all 
cancer types, mutations within TP53 or the retinoblastoma pathway and loss of heterozygosity at 
3p are among the most common, occurring in 50-80% of lung cancers (William D. Travis 2004). 
However, within lung cancer subtypes, specific mutations can dominate. For example, both non-
small cell and small cell lung cancers display mutations in the retinoblastoma pathway. Small 
cell cancers, however, have mutations that result in loss of Rb protein, while non-small cell lung 
cancers rarely display such loss, but instead have a high frequency of inactivating INK4 
mutations (Sherr and McCormick 2002, William D. Travis 2004). While TP53 mutations are 
frequent in both non-small cell and small cell lung cancers, they are more common among 
smokers than never smokers (William D. Travis 2004). 
 A number of other genes have also been shown to influence lung cancer treatment 
response. Specifically, mutations within the epidermal growth factor receptor gene (EGFR) are 
sensitive to tyrosine kinase (TK) inhibitors such as gefitinib and erlotinib and result in increased 
progression-free survival rates compared to traditional chemotherapeutics (Lynch et al. 2004, 
Paez et al. 2004, Pao et al. 2004, Mok et al. 2009). However, some individuals with EGFR 
mutations develop resistance to TK inhibitors as a result of additional EGFR mutations, 
including T790M, and stop responding to treatment (Pao et al. 2005). As a result, next generation 
TK inhibitors that are sensitive even in the presence of acquired resistance mutations are being 
tested (Cross et al. 2014). EGFR mutations are most commonly observed in lung 
adenocarcinoma and are observed at higher frequencies in Asian populations compared to 
European-descent populations (Dearden et al. 2013). Furthermore, EGFR mutations are 
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estimated to be a much as twice as frequent in never/light smokers compared to ever/heavy 
smokers (Dearden et al. 2013). 
 Mutations in KRAS are also common among lung cancer cases, and together with EGFR 
mutations, are estimated to occur in nearly 50% of all lung cancers (Dearden et al. 2013). Like 
EGFR, KRAS mutations are also observed more frequently in adenocarcinoma lung cancers; 
however, mutations in KRAS are more frequent in individuals of European ancestry compared to 
Asian ancestry. KRAS mutations have also been shown to have prognostic value: mutations in 
this gene are associated with poor response to TK inhibitors and may predict organ-specific 
metastasis (Pao et al. 2005, Lohinai et al. 2017). 
 Somatic mutations in several other genes, including HER2, PIK3CA, BRAF, MEK1, ALK, 
and PTEN, have also been identified in lung cancer and may influence lung cancer outcomes 
(Cappuzzo et al. 2006, Ludovini et al. 2011, Marchetti et al. 2011, Cui et al. 2014, Lovly et al. 
2014, Caunt et al. 2015). In turn, assays capturing such information are being developed for the 
clinic as a means of driving genetically informed clinical care for the improvement of lung 
cancer outcomes (Pao and Chmielecki 2010, Su et al. 2011, Levy et al. 2012). 
 
Heritability and Family Studies 
 While somatic variation inarguably plays a large role in lung cancer development, 
progression, and treatment, evidence for an inherited component to lung cancer also exists. 
Studies of lung cancer risk in families show a two- to three-times increased risk with at least one 
first-degree relative with lung cancer (Tokuhata and Lilienfeld 1963, Ooi et al. 1986, Cannon-
Albright et al. 1994, Schwartz et al. 1996, Etzel et al. 2003, Cote et al. 2005, Matakidou et al. 
2005, Nitadori et al. 2006, Chen and Kaphingst 2011, Cote et al. 2012). These associations 
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persist even after adjustment for smoking (Lorenzo Bermejo and Hemminki 2005). Furthermore, 
a twin study identified a heritability estimate of ~14% (Hemminki et al. 2001), while analysis of 
heritability in genome-wide association studies reveals as much as 20% heritability for lung 
cancer (Sampson et al. 2015).  
 The first family-based linkage study for lung cancer was conducted in 2004 and 
identified a significant association on chromosome 6q23-25 (Bailey-Wilson et al. 2004). The 
authors observed that the strength of the association was directly proportional to number of 
affected individuals within each pedigree (Bailey-Wilson et al. 2004). Fine mapping of the 6q23-
25 region localized the signal to the RGS17 gene, which showed increased expression in sporadic 
lung tumors (You et al. 2009). Haplotypes within this region were associated with increased risk 
among never and light smokers, suggesting an interaction between smoking status and inherited 
risk at this region (Amos et al. 2010). 
 
Genome-wide association studies 
 The first genome-wide association studies (GWAS) for lung cancer risk were published 
in 2008 in a series of three papers (Amos et al. 2008, Hung et al. 2008, Thorgeirsson et al. 2008). 
All three groups reported an association between chromosome 15q25 and increased lung cancer 
risk in European-descent populations. Thorgeirsson et al. also showed an association with 
smoking quantity and nicotine dependence, suggesting gene-environment interactions in the 
etiology of lung cancer. Hung et al., on the other hand, observed similarly increased lung cancer 
risk at this locus even among never smokers and estimated an attributable risk of approximately 
14%. The 15q25 locus is a region of strong linkage disequilibrium containing numerous genes, 
including several nicotinic receptor subunit genes. Several studies have attempted to clarify the 
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relationship between the 15q25 locus, smoking behaviors, and lung cancer risk, and have 
subsequently confirmed a direct relationship between genetic variation at 15q25 and lung cancer 
risk (Spitz et al. 2008, Lips et al. 2010, Saccone et al. 2010, Wang et al. 2010, VanderWeele et 
al. 2012).  
 Since the initial lung cancer GWAS a number of additional risk loci have been identified. 
Perhaps one of the most consistently replicated (other than 15q25, of course) is 5p15.33, which 
was first reported by McKay et al. (2008). The study identified two variants in this region in high 
linkage disequilibrium, both of which had odds ratios near 1.2 per risk allele (McKay et al. 
2008). Numerous studies have reported similar associations (Broderick et al. 2009, Landi et al. 
2009, Hsiung et al. 2010, Yoon et al. 2010, Hu et al. 2011, Lan et al. 2012, Li et al. 2013, Zhao 
et al. 2014). The two genes most commonly implicated in this region are TERT (telomerase 
reverse transcriptase) and CLPTM1L (cleft lip and palate transmembrane protein 1 like protein). 
TERT combines with TERC (telomerase RNA component) to form telomerase, an enzyme 
responsible for maintaining telomere structure through the addition of TTAGGG repeats to 
chromosome ends (Feng et al. 1995, Harrington et al. 1997, Lingner et al. 1997). Telomerase is 
usually absent in somatic tissues, but has been shown to be active in rapidly dividing cancer 
cells. Telomerase and telomere-related proteins have been heavily implicated in cancer (Shay 
and Wright 2011, Jafri et al. 2016).  
 Genome-wide association studies have identified additional lung cancer risk loci on 
chromosomes 3q28-9, 6p21, 6q22.2, 9p21.3, 10q25.2, 12q13.13, 12q23.1, 13q12.12, 18p11.22, 
and 22q12.2 (Broderick et al. 2009, Landi et al. 2009, Yoon et al. 2010, Hu et al. 2011, Ahn et al. 
2012, Lan et al. 2012, Timofeeva et al. 2012, Dong et al. 2013, Wang et al. 2016). Other studies 
! 15 
have reported increased lung cancer risk for variants associated with smoking-related metabolites 
(Park et al. 2015, Patel et al. 2016).   
 Several studies have also sought to identify genetic variants associated with lung cancer 
survival, with particular emphasis on response to lung cancer treatments. Niu et al. (2012) 
performed a genome-wide association study for cytotoxicity induced by paclitaxel and docetaxel, 
two common chemotherapeutics used in lung cancer treatment, in lymphoblastic cell lines. 
Significant SNPs were then examined in a population of small and non-small cell lung cancer 
patients. Functional interrogation of the most significant associations identified multiple SNPs 
associated with survival response, including variation that resulted in desensitization to paclitaxel 
in cell lines (Niu et al. 2012). Additional genetic variants associated with survival have been 
identified for both small cell (Wu et al. 2010, Han et al. 2014)and non-small cell lung cancers 
(Sato et al. 2011, Wu et al. 2011, Hu et al. 2012, Lee et al. 2013, Tang et al. 2015).  
 
Pleiotropy studies of lung cancer 
 Genetic studies of lung cancer risk have recently turned to investigating pleiotropy, 
which occurs when a single variant or locus is associated with more than one phenotype 
(Solovieff et al. 2013). A 2012 study consisting of ~18,000 lung cancer cases and ~60,000 
controls of European descent tested 165 SNPs previously associated with at least one other type 
of cancer for an association with lung cancer risk (Park et al. 2014). Their results confirmed risk 
loci at 5p15.33 (TERT gene) and 9p21 (CDKN2B-AS1 gene) and identified one novel 
association: a variant in the LSP1 gene previously associated with breast cancer risk (Park et al. 
2014). A genome-wide association study of lung, gastric, and esophageal cancers found evidence 
for pleiotropy at chromosomes 6p21.1 and 7p15.2, suggesting these loci are important in 
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multiple cancer types (Jin et al. 2012). Finally, a large study of lung, ovary, breast, prostate, and 
colorectal cancer cases and controls, reported a shared risk locus at 1q22 for lung and breast 
cancers (Fehringer et al. 2016). Furthermore, Fehringer et al. (2016) also confirmed known lung 
cancer risk loci in the BRCA2 gene (shared between lung and ovarian cancers) and in the 
CDKN2B-AS1 gene (shared between lung and prostate cancers), which was also reported as 
pleiotropic by Park et al.  
 
Genetics of lung cancer in African Americans 
 Family studies comparing European- and African-descent populations revealed a nearly 
two-fold increased risk for African American first-degree relatives of lung cancer patients 
compared to their white counterparts (Cote et al. 2005). Despite evidence for increased risk and 
poorer survival compared to other racial/ethnic groups, relatively few genetic studies of lung 
cancer have been conducted in African Americans, and most have focused on candidate genes or 
confirming associations previously identified in European or Asian descent populations (Spitz et 
al. 2013, Walsh et al. 2013). Schwartz et al. (2009) confirmed 15q25 as a lung cancer risk locus 
in African Americans, which persisted even when controlling for smoking status. Walsh et al. 
(2012) similarly confirmed 15q25, but also identified novel risk associations in CHRNA1 on 
chromosome 2, while Walsh et al. (2013) provided evidence for histology-specific associations 
for the previously identified 5p15.33 and 6p22.1-21.31 risk loci. A genome-wide admixture 
mapping study reported associations with lung cancer risk for a region with excess European 
ancestry on chromosome 1 among female non-small cell lung cancer cases and a region with 
excess African ancestry on chromosome 3q among ever smoking non-small cell lung cancers 
(Schwartz et al. 2011). However, the first African American genome-wide association study of 
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lung cancer was conducted in 2016 (Zanetti et al. 2016). The largest study of African American 
lung cancer to date, Zanetti et al. failed to identify novel lung cancer risk loci, but confirmed 
associations with 15q25 and 5p15.33. Furthermore, while genetic studies of lung cancer risk in 
African Americans are few, they are completely lacking for studies of lung cancer survival.  
 
Admixed Populations 
Genetic Admixture 
 The vast majority of genetic epidemiologic studies tend to group individuals by race or 
race/ethnicity, with the most common classifications in the United States being white (or non-
Hispanic white), black (or non-Hispanic black), Asian/Pacific Islander, American Indian/Alaska 
Native, and Hispanic. Such classifications do an adequate job accounting for differing social and 
cultural norms observed between populations. However, given recent reports that have estimated 
as many as 94-98% of individuals today have at least some degree of mixed ancestry, 
predetermined race classifications poorly represent underlying genetic architecture within each 
racial group (Shriner et al. 2014, Baker et al. 2017).  
 Genetic admixture occurs when two previously isolated populations begin mating 
(Winkler et al. 2010). Multiple generations of random mating and recombination have left 
modern day descendants with mosaic chromosomes, in which chromosomal segments of one 
ancestry are interspersed between chromosomal segments of the other ancestry  (Figure 6) 
(Winkler et al. 2010). Within the United States, most individuals, including individuals of 
European ancestry, exhibit some degree of genetic admixture (Bryc et al. 2015). The admixture 
event(s) responsible for the African American population is estimated to have occurred in the 
South prior to the start of the Civil war (Baharian et al. 2016). Admixture estimates for self-
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identified African Americans have consistently approximated 80% African ancestry and 20% 
European ancestry, though these estimates can range from less than 1% to nearly 99% European 
ancestry (Tishkoff et al. 2009, Bryc et al. 2010). Thus a high degree of genetic diversity exists 
even within self-identified racial/ethnic groups.  
 
Importance of ancestry in biomedical research 
 The discovery of ancestry informative markers, genetic variants that have substantially 
different allele frequencies between populations, has allowed for the estimation of ancestry at the 
individual level. While there are many methods for estimating ancestry, they can be grouped into 
two categories: those that estimate global ancestry (Pritchard et al. 2000, Price et al. 2006, 
Alexander et al. 2009) and those that estimate local ancestry (Pasaniuc et al. 2009, Maples et al. 
2013). Local ancestry estimation, which assigns ancestry to each position in the genome, has 
shown utility through admixture mapping studies to identify genetic variants associated with 
racial disparities in disease prevalence (Schwartz et al. 2011, Molineros et al. 2013, Velez 
Edwards et al. 2014, Ruiz-Narvaez et al. 2016).  
 While global ancestry is most commonly used in controlling for confounding by 
population substructure in genetic association studies, several studies have shown strong 
associations between global ancestry estimates and biomedical phenotypes (Signorello et al. 
2010, Goetz et al. 2014, Dumitrescu et al. 2015). In a population of African Americans, Kumar 
et al. showed that global African ancestry was inversely associated with lung function through 
FEV1 and forced vital capacity (2010). Associations between population structure and lung 
function were also observed in Mexican populations (Moreno-Estrada et al. 2014). Similarly, 
Yang et al. showed that increased proportions of Native American ancestry are associated with 
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acute lymphoblastic leukemia relapse in children (2011). Such associations with genetic ancestry 
have also been noted for breast cancer (Fejerman et al. 2008, Fejerman et al. 2013) and coronary 
artery disease (Peralta et al. 2010), to name a few. The role of genetic ancestry in lung cancer 
survival remains to be examined. 
 
Motivation for the research 
Racial disparity in lung cancer 
 As stated earlier, a racial disparity exists in both lung cancer risk and survival, such that 
blacks have increased incidence and poorer survival compared to whites (Howlader N , 
American Cancer Society 2017). Black males are diagnosed at earlier ages and later stages 
compared to their white counterparts (Howlader N , Efird et al. 2014, Ganti et al. 2014). 
Furthermore, studies show blacks are less likely to receive stage-appropriate treatments 
compared to whites (Hardy et al. 2009, Ganti et al. 2014) and have poorer 5-year lung cancer 
survival rates (Howlader N , Aizer et al. 2014, Zeng et al. 2015, American Cancer Society 2017). 
However, several studies suggest that the observed racial disparity in lung cancer mortality 
would diminish with equal access to healthcare between blacks and whites (Zheng et al. 2012, 
Caposole et al. 2014, Ganti et al. 2014, Hua et al. 2014). Other published findings demonstrate 
there is no difference in lung cancer mortality rates between blacks and whites when stage and 
treatment are accounted for (Bach et al. 1999, Aldrich et al. 2013), though these results are in 
contrast to a recent study of SEER data consisting of >150,00 individuals in which African 
Americans continued to have poorer survival even after controlling for stage and treatment 
(Aizer et al. 2014). Thus continued research is necessary to better understand the observed racial 
disparity in lung cancer survival. 
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Importance of racially diverse populations in genetic research 
 The present work is made relevant by the need to include racially diverse populations in 
biomedical research. A 2016 analysis of genome-wide association studies revealed that only 19% 
of studies are conducted in individuals of non-European ancestry, of which only 3% were 
conducted in African-descent populations (Popejoy and Fullerton 2016). This is especially 
concerning given the recent studies highlighting issues with assuming equivalent genetic risk 
across racial/ethnic groups. Specifically, Manrai et al. examined diagnostic sequence variants for 
hypertrophic cardiomyopathy, which were originally detected in white populations, and found 
that benign mutations misdiagnosed as pathogenic were most common among African 
Americans and resulted in incorrect positive diagnoses (2016). Furthermore, Martin et al. 
recently calculated polygenic risk scores in diverse populations for several well-studied 
phenotypes and found that risk is most accurately estimated in populations matching the 
population from which the score was derived (2017). For several traits, calculated polygenic risk 
scores were in direct opposition to clinical and anthropological evidence (Martin et al. 2017). 
While non-transferability of genetic risk factors across diverse populations can result for multiple 
reasons, including differing linkage disequilibrium patterns or allele frequencies, these studies 
highlight the need for including racially diverse populations such as African Americans in 
genetic research, or, at the very least, conducting cross-population validation studies to confirm 
known associations. Furthermore, despite strong evidence that blacks are at increased risk and 
have poorer outcomes, few lung cancer genetics studies have been conducted in African 
American populations. We aim to address this dearth of lung cancer research conducted among 
African Americans 
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Research aims to be addressed 
 This dissertation seeks to examine the role of genetics in lung cancer survival and risk in 
African Americans through three independent studies: 
1. Examine the role of African genetic ancestry compared to other known contributors 
to lung cancer survival in a population of whites and blacks (Chapter 2). 
2. Examine variants previously associated with lung cancer survival and identify novel 
common and rare variants associated with lung cancer survival in an African 
American population (Chapter 3). 
3. Investigate cross-cancer pleiotropic associations for lung cancer risk in African 
Americans (Chapter 4).  
Only by increasing our understanding of how genetic ancestry impacts lung cancer survival 
compared to known social, environmental, or clinical risk factors, will we be able to adequately 
address (and ultimately remove) the observed racial disparity. Furthermore, previous studies 
have revealed the non-transferability of genetic risk factors across racial/ethnic groups (Manrai et 
al. 2016, Martin et al. 2017); thus, it is of utmost importance to examine genetic risk factors of 
lung cancer survival and risk directly in African Americans. Such efforts may ultimately lead to 
better treatments (in the case of survival-associated variants) or improved cancer detection or 
prevention (in the case of risk-associated variants). 
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Table 1. Overall frequency of lung carcinoma by histologic subtype and stage at Modified 
from William D. Travis (2004) and (Howlader N). 
Stage Adenocarcinoma Squamous Cell Large Cell Small Cell 
Overall, % 46.6 23.2 1.6 13.1 
Localized, % 22.2 21.5 15.2 8.2 
Regional, % 33.1 38.5 31.5 26.1 
Distant, % 35.9 25.2 40.3 52.8 
Unstaged, % 8.8 14.8 12.9 12.8 
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Table 2. Known lung cancer carcinogens in humans with exposure type and examples of 
the industry in which the agent is used. 
Agent 
Exposure 
Type Industry/Use** 
Ionizing radiation 
   Radon 
   Plutonium 
   X- and gamma-rays 
 
E, O 
O 
E, O 
 
Mining 
Nuclear 
Medical, nuclear 
Chemicals and Mixtures 
   Bis(chloromethyl)ether;  
      chloromethyl methyl ether 
   Coal-tar pitch 
   Soot 
   Sulfur mustard 
   Diesel exhausts 
 
 
O 
O 
O 
O 
E, O 
 
 
Chemical Production 
Construction, electrodes 
Pigments, chimney sweeps 
Military 
Mining, trucking, construction 
Metals 
   Arsenic and arsenic compounds 
   Beryllium and beryllium compounds 
   Cadmium and cadmium compounds 
   Chromium (VI) compounds 
   Nickel compounds 
 
E, O 
O 
O 
O 
O 
 
Glass, metals, pesticides, textiles 
Aerospace, automotive, biomedical 
Dye/pigment, welding, batteries 
Metal planting, dye/pigment 
Metallurgy, alloy, catalyst 
Dust and fibers 
   Asbestos 
   Sillica dust, crystalline 
 
E, O 
E, O 
 
Insulation, construction, textiles 
Stone cutting, mining, glass, paper 
Occupations 
   Aluminum production 
   Coal gasification 
   Coke production 
   Hematite mining 
   Iron and steel founding 
   Painting 
   Rubber production industry 
 
O 
O 
O 
O 
O 
O 
O 
 
 
Adapted from (William D. Travis 2004, Field and Withers 2012); E=environmental exposure; 
O=occupational exposure 
*Examples; not intended to be inclusive of all possible uses or industries. 
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Figure 1. Estimated frequency of new lung cancer cases and deaths by cancer site for 2017. 
Data from American Cancer Society (2017).  
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Figure 2. Stage distribution by race, (2007-2013). Data!from!Howlader!N!(2017).!
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Figure 3. Age-specific SEER Incidence rates (2010-2014), by race and sex. Rates!per!100,000.!Data!from!Howlader!N!(2017).!
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Figure 4. Age-adjusted SEER incidence rates by race and sex. Rates!per!100,000.!Data!from!Howlader!N!(2017).!
!
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Figure 5. Age-adjusted U.S. death rates by race and sex. 
Rate per 100,000. Data from Howlader N (2017).  
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Figure 6. Mating between two previously isolated ancestors results in admixed offspring, 
the effects of which are observable in modern day descendants. 
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CHAPTER 2 
 
NO EVIDENCE FOR AN ASSOCIATION BETWEEN AFRICAN GENETIC 
ANCESTRY AND LUNG CANCER SURVIVAL 
 
Introduction 
Epidemiology of lung cancer survival 
Lung cancer is the leading cause of cancer death among both men and women in the 
United States and worldwide, with a 5-year relative survival of 18% (Howlader N , Stewart et al. 
2014, Henley et al. 2015). Several factors can influence lung cancer survival rates, but among the 
most important is stage of diagnosis. Individuals diagnosed with local stage disease have a 55% 
five-year survival rate, while only 4% of individuals diagnosed with distant stage disease survive 
up to 5 years (Howlader N , American Cancer Society 2017). These statistics are made even 
more harrowing by the low frequency of early stage diagnoses compared to late stage diagnoses: 
16% of lung cancers are diagnosed at local stage disease, 22% at regional stage, and 57% at 
distant stage (Howlader N , American Cancer Society 2017). 
 
Racial disparity in lung cancer survival 
While lung cancer mortality has decreased in all races in recent years in large part due to 
greater smoking cessation efforts, a racial disparity continues to exist such that blacks experience 
poorer survival compared to whites (Moolgavkar et al. 2012, Aizer et al. 2014, Henley et al. 
2015, American Cancer Society 2017). Specifically, the national five-year survival is 19% 
among white individuals and 16% among blacks (Howlader N). Blacks are more frequently 
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diagnosed at late stage disease compared to whites and less likely to receive the recommended 
course of treatment based on disease stage (Howlader N , Halpern et al. 2008, Hardy et al. 2009, 
Efird et al. 2014). Several recent studies have suggested that controlling for differential access to 
healthcare results in no difference in survival outcomes among blacks and whites (Zheng et al. 
2012, Caposole et al. 2014, Ganti et al. 2014). We and others have demonstrated blacks and 
whites experience no difference in lung cancer survival after controlling for stage and 
socioeconomic factors (Aldrich et al. 2013, Hua et al. 2014). A recent analysis of Surveillance, 
Epidemiology, and End Results (SEER) Program data also suggests that blacks have similar lung 
cancer survival compared to whites (Zeng et al. 2015). 
 
Admixture in African Americans 
 Blacks in the United States are an admixed population with varying proportions of 
African ancestry (Tishkoff et al. 2009, Bryc et al. 2010) and self-identified whites can carry 
African ancestry (Bryc et al. 2015). Identification of ancestry informative markers, genetic 
variants that differ in frequency between ancestral populations, allows us to distinguish 
individual-level ancestral origins at the genetic level, i.e. genetic ancestry. Prior studies have 
shown important associations between genetic ancestry and biomedical phenotypes (Peralta et al. 
2010, Goetz et al. 2014, Dumitrescu et al. 2015) such as lung function (Salari et al. 2005, Kumar 
et al. 2010, Moreno-Estrada et al. 2014) and breast cancer risk (Fejerman et al. 2008, Fejerman et 
al. 2013). 
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Rationale 
While the association between race and lung cancer survival has been described in 
several studies, including large, population-based cohorts, the association between genetic 
ancestry and survival after a diagnosis of lung cancer has yet to be examined. We examined the 
effect of African ancestry on lung cancer survival in blacks and whites with non-small cell lung 
cancer in the Southern Community Cohort Study (SCCS), a cohort with the largest 
representation of blacks in the United States. Black and white SCCS participants were largely 
recruited from community health centers and thus have similar access to healthcare. Analyses 
were replicated in a population of black lung cancer cases ascertained from the population-based 
Metropolitan Detroit Cancer Surveillance System. 
 
Methods 
Study population: the Southern Community Cohort Study 
Study participants were selected from the SCCS, a prospective cohort study of ~86,000 
adults. Participants were enrolled between March 2002 and September 2009 from a 12-state 
region across the Southeastern United States (Alabama, Arkansas, Florida, Georgia, Kentucky, 
Louisiana, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, and West Virginia). 
Approximately 15% of participants were recruited through mail-in questionnaires, which were 
sent to a random subset of adults across the 12-state region. The remaining 85% of participants 
were enrolled at community health centers throughout the region. Demographic characteristics, 
family history of disease, insurance coverage, tobacco use and other information were collected 
via in-person interviews by a trained interviewer upon enrollment at the health centers. 
Individuals self-reported race/ethnicity by selecting any of the following investigator-defined 
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racial/ethnic groups: white, black/African American, Hispanic/Latino, Asian or Pacific Islander, 
American Indian or Alaska Native, or Other racial or ethnic group.  Approximately two-thirds of 
participants self-identified as “Black/African American”. Upon enrollment, all individuals were 
asked to donate a biologic specimen (blood, urine, saliva, or buccal cell), of which ~90% of 
participants agreed. Individuals were eligible to participate if there were between the ages of 40-
79 years. A detailed description of study design and recruitment has been previously published 
(Signorello et al. 2005, Signorello et al. 2010). The SCCS was approved by institutional review 
boards at Vanderbilt University and Meharry Medical College. Written informed consent was 
obtained from all participants.  
 
Case Identification and Mortality Assessment  
All incident non-small cell lung cancer (NSCLC) cases occurring within the SCCS 
between 2002 and 2010 were identified through linkage with the 12 state cancer registries. 
Individuals with a lung cancer diagnosis prior to study enrollment were excluded. Histology, 
stage at diagnosis, and treatment information were obtained from individual state cancer 
registries. Stage was derived using the American Joint Committee on Cancers (AJCC) TNM 
System staging guidelines (6th and 7th Editions). Due to small sample size, we combined 
individuals with stage II and III disease. For individuals missing stage information, we used the 
Surveillance, Epidemiology, and End Results (SEER) Summary Stage guidelines, assuming local 
disease was equivalent to stage I, regional disease was equivalent to stage II/III, and distant 
disease was equivalent to stage IV. Treatment information describing the administration of 
chemotherapy, radiation therapy, hormone therapy, immunotherapy, surgery, or other cancer-
directed treatment was summarized into a design variable with five levels: no treatment, 
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chemotherapy only, radiation only, surgery only, and multi-modality (patients receiving any 
combination of the above treatment options). Participants were followed for all-cause mortality. 
Vital status was determined at end-of-follow-up (December 31, 2011) through linkage with the 
Social Security Administration or the National Death Index. Survival time was defined as the 
time from the date of diagnosis to the date of death, loss to follow up, or censoring.  
 
Genotyping and Quality Control 
SCCS individuals were genotyped on the Illumina HumanExome BeadChip v1.1, which contains 
a panel of >3,000 ancestry informative markers for distinguishing between African and European 
ancestries. Briefly, quality control removed individuals with sex inconsistencies, <98% 
genotyping, or self-reported race other than “Black/African American” or “White”. Relatedness 
among individuals was also examined and the individual with the lowest call rate in each 
relationship pair was removed. Variants were removed during quality control if they were non-
autosomal, had <98% genotyping efficiency, or <5% minor allele frequency. Mendelian errors 
were examined using HapMap trio controls. All quality control measures described were applied 
using PLINK (Purcell et al. 2007) (version 1.07). 
 
Ancestry Estimation 
Global ancestry estimates describe the proportion of an individual’s total genome 
inherited from each contributing ancestral population. To distinguish European and African 
ancestry, we used a panel of ancestry informative markers. After standard quality control 
filtering (minor allele frequency > 0.05, genotyping efficiency > 98%, Hardy-Weinberg 
equilibrium p > 0.00001) and pruning based on linkage disequilibrium (window size = 50 SNPs, 
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step size = 10 SNPs, r2 < 0.4), a total of N=553 markers were available for whites and N=1137 
for blacks for global ancestry estimation. Supervised admixture analysis was performed using the 
software program ADMIXTURE (Alexander et al. 2009) to estimate individual ancestry 
proportions assuming two ancestral populations with CEU (Utah residents with ancestry from 
northern and western Europe) and YRI (Yoruban in Ibadan, Nigeria) HapMap (International 
HapMap Consortium 2003) populations as representative ancestral populations. The resulting 
output contains the estimated proportions of African and European ancestry for each individual; 
proportion of African ancestry was then converted to a percent and used for survival analyses 
(hereafter referred to as “African ancestry”).  
 
Statistical Analysis 
The impact of African ancestry on overall survival among self-reported black and white 
lung cancer cases was examined using Cox proportional hazards models. Individuals with less 
than 30-day survival time were excluded from analysis to remove potential bias related to 
treatment effects. We first estimated the time-dependent area under the curve (AUC) for an 
unadjusted Cox proportional hazards model assessing the impact of African ancestry on overall 
survival. We then derived a multivariable model (hereafter called the “main effects model”), 
examining African ancestry and overall survival, adjusting for age at diagnosis, sex, BMI 
(kg/m2), number of cigarettes per day, stage at diagnosis, treatment, highest education level, and 
family history of lung cancer. Covariates were selected based on a priori knowledge.  Using a 
flexible parametric additive model, it was determined that self-reported race could be predicted 
from African ancestry and the other model covariates, so we only included the continuous 
measurement of African genetic ancestry in the Cox regression models.  All continuous 
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variables, including African ancestry, were modeled with restricted cubic splines using three 
knots. Missing data was multiply imputed ten times using predictive mean matching among the 
eight confounding variables.  The survival models were fit with each of the 10 completed data 
sets, and results were pooled using Rubin’s rules (Rubin 2009).  A time-dependent receiver 
operating characteristic (ROC) curve (Heagerty et al. 2000) and AUC was calculated for every 
time point between 30 days and 4 years to estimate how well the model predicts survival. The 
time-dependent AUCs were then averaged over the time interval to obtain the average time-
dependent AUC.  We then compared the time-dependent AUC of our main effects model to an 
over-fit Cox proportional hazards model with two-way interaction terms (i.e. African ancestry x 
treatment, African ancestry x stage, African ancestry x education, education x treatment, 
education x stage, treatment x stage, sex x age, sex x BMI and sex x cigarettes per day) to assess 
how well our main effects model performed. We examined the impact of African ancestry, stage, 
and treatment by removing these variables from the model and compared the time-dependent 
AUC with and without these variables. A subgroup analysis was performed among self-reported 
black individuals only. All statistical analyses were carried out in R version 3.2.2 with packages 
Hmisc and survivalROC.  
 
Replication 
Incident black NSCLC cases were identified from three lung cancer case-control studies 
(Family Health Study III; Women’s Epidemiology of Lung Disease Study; and Exploring 
Health, Ancestry and Lung Epidemiology Study) conducted at the Barbara Ann Karmanos 
Cancer Institute (KCI) affiliated with Wayne State University (WSU) in Detroit, MI. These 
studies have been previously described (Schwartz et al. 2009). Rapid case ascertainment was 
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used to identify cases in the population-based Metropolitan Detroit Cancer Surveillance System, 
an NCI-funded SEER registry. The institutional review board at Wayne State University 
approved this study and written informed consent was provided by all participants. Stage, 
treatment, and vital status were obtained through linkage with the Detroit SEER registry. 
Treatment and stage variables were summarized in the same manner as the SCCS using both 
AJCC and SEER staging information. Individuals were previously genotyped on the Illumina 
1M-Duo BeadChip. Supervised analysis (K=2) was performed with the use of genome-wide 
single nucleotide polymorphisms, CEU and YRI reference populations, and the software 
program ADMIXTURE. Time-dependent AUCs were estimated using the same methods 
described above for the KCI/WSU population alone and combined with the SCCS population.  
 
Results  
Descriptive characteristics 
Among the SCCS individuals, 450 incident NSCLC cases occurred with 425 (286 black 
and 139 white) remaining after quality control procedures. Individuals had a median survival 
time of 0.7 years (range: 0.003-8.6 years), during which 359 deaths occurred (248 blacks and 
111 whites). Forty-two individuals (32 black and 10 white) were excluded for having survival 
times less than 30 days. Forty-seven percent of blacks with lung cancer had less than 12 years of 
education compared to 35% of whites (Table 3).  The mean age at lung cancer diagnosis was 60 
years for blacks and 63 years for whites. More males were diagnosed with lung cancer among 
blacks than among whites (60% vs. 42%). Smoking status (current/former/never) did not differ 
between blacks and whites, with 94% of blacks and 96% of whites having smoked cigarettes. 
Twenty-three percent of whites reported a first-degree relative with a history of lung cancer 
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compared to 9% of blacks. A greater percentage of blacks were diagnosed at stage IV disease 
compared to whites (52% vs. 43%). Although similar numbers of blacks and whites were 
diagnosed with stage I disease (16% vs. 21%), almost twice as many whites received a surgery 
only course of treatment compared to blacks (11% vs. 21%) (Figure 7). Median African ancestry 
for self-reported blacks was 85.6%, and was 1.3% for self-reported whites (Table 3 and Figure 
8).  
 
Survival analysis 
Cox proportional hazards models were implemented to determine the impact of African 
ancestry on overall survival. The unadjusted Cox model for percent African ancestry had an 
average time-dependent AUC of 0.54 (Table 4). In the main effects model, African ancestry was 
not associated with overall survival, with or without stage and treatment (Figure 9A-B), although 
at smaller values of African ancestry a reduction in mortality was observed. We then estimated 
the area under the curve to assess the predictive ability of each model. With an average time-
dependent AUC of 0.79, the main effects multivariable model examining the association between 
African ancestry and overall survival, performed dramatically better than the univariate model 
with African ancestry alone (Figure 10). The inclusion of interaction terms to the main effects 
model to create an “over fit” model increased the average time-dependent AUC slightly to 0.83, 
indicating that the main effects model had high predictive ability. Removing African ancestry 
had no impact on the average time-dependent AUC for either the main effects model (Table 4 
and Figure 10) or the interactions model (Table 4). Removing stage and treatment from the main 
effects model substantially decreased the average time-dependent AUC to 0.65. Further removal 
of African ancestry from the main effects model without stage and treatment resulted in little 
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change in the average time-dependent AUC (Figure 10). We then removed whites from the 
SCCS and examined each of the Cox proportional hazards models among blacks only. 
Observations were similar to those of the overall NSCLC population and are presented in Figure 
11 and Table 5.   
 
Replication analysis 
 We evaluated the impact of African ancestry on overall survival in a population of 316 
black NSCLC cases ascertained from the KCI/WSU. Briefly, the mean age of diagnosis was 60 
years and 41% of lung cancer cases were male. Thirty-four percent of cases were diagnosed at 
stage I disease, 39% were diagnosed at stage II/III disease, and 26% were diagnosed at stage IV 
disease (Table 6 and Figure 7). The median African ancestry was 83.3% (Figure 12). Additional 
descriptive characteristics of this population are provided in Table 6.  Similar findings for the 
impact of African ancestry on overall survival were observed in the blacks in the SCCS (Table 5 
and Figure 13). Removal of African ancestry from both the main effects model and the 
interaction model had a negligible effect on the average time-dependent AUC (0.74 and 0.76, 
respectively, Table 5). Similar to the SCCS, the removal of stage and treatment from the main 
effects model resulted in a dramatic decrease in the average time-dependent AUC (0.63) and 
removal of African ancestry in addition to stage and treatment had little impact (average time-
dependent AUC = 0.61).  
 We further examined the impact of African ancestry on survival in a combined SCCS and 
KCI/WSU population. Average time-dependent AUCs are presented in Table 7 and Figure 14. 
There was no difference in average time-dependent AUCs for any model compared to SCCS or 
WSU populations alone. 
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Discussion 
 We found that African ancestry was not associated with NSCLC survival in the SCCS, 
using Cox proportional hazard models adjusted for stage and treatment. Since African ancestry 
did not have a linear relationship with survival, we chose to model the predictor as a restricted 
cubic spline. As such, there is no single hazard ratio and p-value to describe the magnitude and 
significance of the association. Instead, we present the hazard ratio and confidence interval as a 
function of African ancestry in Figure 9, using the median African ancestry value as the referent. 
Furthermore, we examined the impact of African ancestry on survival by comparing the average 
time-dependent area under the curve for Cox proportional hazards models with and without 
African ancestry or stage and treatment. This allows us to examine the clinical utility of such 
predictors, rather than simply the strength of the association. Using these methods, we find that 
stage and treatment were strongly predictive of overall survival and are more important 
predictors of survival than African ancestry. This result was recapitulated in an independent 
population of blacks with NSCLC from KCI/WSU, providing further evidence of the null 
association between African ancestry and overall survival.  
In this study we used genetic ancestry as a continuous proxy for race. While genetic 
ancestry and race are highly correlated, race can be viewed as a social construct that captures 
both genetic and non-genetic factors, such as culture and social perception. Given the high 
variability of genetic admixture that is not captured by categorically-defined race, adjusting for 
race alone while examining diseases with established racial disparities may not entirely account 
for underlying population substructure. Here, the utilization of African ancestry instead of race 
allows us to attempt to disentangle the genetic and social disparities associated with lung cancer 
survival. We find that African ancestry is not associated with overall survival when adjusting for 
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stage and treatment (Figure 9A), with hazard ratios and confidence intervals encompassing 1.0 
for all values of African ancestry. When stage and treatment are removed from the model (Figure 
9B), we observed a slightly, although not statistically significant, greater survival for individuals 
with smaller proportions of African ancestry in the SCCS. We hypothesize that this observed 
reduction in mortality is due to the influence of unmeasured treatment, social, environmental, or 
other factors not captured by genetic ancestry alone. It is possible that these observed differences 
are the result of cultural differences in the perception of disease and the willingness to seek 
treatment (Margolis et al. 2003, Lathan et al. 2010).  
Herein we observed a striking decrease in clinical validity when stage and treatment are 
excluded from overall survival models for lung cancer. Previous work by our group and others 
has shown that racial disparities in lung cancer survival disappear when controlling for stage at 
diagnosis or treatment (Zheng et al. 2012, Aldrich et al. 2013, Ganti et al. 2014). Together these 
studies along with the present analysis suggest that the observed disparity in survival between 
blacks and whites can be attributed to differences in stage at diagnosis or receipt of treatment 
rather than race. It is important to note that while this study shows no association between 
genetic ancestry and overall survival, it does not eliminate the potential for a genetic contribution 
to lung cancer survival or the possibility of race-specific genetic risk factors.   
 To our knowledge, this is the first study to examine the relationship between genetic 
ancestry and lung cancer survival in blacks and whites with NSCLC. By utilizing the unique 
SCCS, we were able to control for multiple factors potentially influencing lung cancer survival, 
including socioeconomic status, family history of lung cancer, cigarette smoking, disease stage, 
and treatment received. While our study was limited by small sample size, our confidence 
intervals are narrow and the consistency of our findings between two independent study 
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populations, despite the different demographic and epidemiologic characteristics, emphasizes the 
robustness of our findings. Furthermore, we acknowledge that the staging and treatment 
information obtained through linkage with cancer registries may not depict the most accurate and 
up to date clinical and staging information. Future studies should focus on a clinical population 
with carefully annotated clinical information for examining ancestral differences in lung cancer 
survival. 
 In summary, we find that African ancestry is not associated with NSCLC survival and 
that stage and treatment are robust predictors of lung cancer survival. These findings suggest that 
efforts to increase the early detection of lung cancer will improve lung cancer outcomes for both 
blacks and whites.  
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Table 3. Descriptive characteristics by race of incident non-small cell lung cancer (NSCLC) 
cases in the Southern Community Cohort Study. 
 Blacks  
(N=286) 
N (%) 
Whites  
(N=139) 
N (%) 
Total 
(N=425) 
N (%) 
Sex    
       Male 171 (59.8) 58 (41.7) 229 (53.9) 
       Female 115 (40.2) 81 (58.3) 196 (46.1) 
Vital status    
       Alive 38 (13.3) 28 (20.1) 66 (15.5) 
       Dead 248 (86.7) 111 (79.9) 359 (84.5) 
Median African ancestry, % (range) 85.6  
(<0.01-98.7) 
1.3 
(<0.01-91.1)  
80.1  
(<0.01-98.7) 
Lung cancer stage at diagnosis    
       I 44 (15.7) 29 (21.3) 73 (17.5) 
       II/III 90 (32.0) 49 (36.0) 139 (33.3) 
       IV 147 (52.3) 58 (42.6) 205 (49.2) 
       Unknown 5 3 8 
Treatment    
       No treatment 75 (26.8) 36 (27.3) 111 (26.9) 
       Surgery only 31 (11.1) 27 (20.5) 58 (14.1) 
       Chemotherapy only 51 (18.2) 18 (13.6) 69 (16.7) 
       Radiation only 36 (12.9) 12 (9.1)  48 (11.7) 
       Multi-modality 87 (31.1) 39 (29.5) 126 (30.6) 
       Unknown 6 7 13 
Histology    
       Adenocarcinoma 113 (39.5) 51 (36.7) 164 (38.6) 
       NSCLC-NOS 78 (27.3) 34 (24.5) 112 (26.4) 
       Squamous 72 (25.2) 41 (29.5) 113 (26.6) 
       Other NSCLC  22 (7.7) 12 (8.6) 34 (8.0) 
       Multiple histologies 1 (0.3) 1 (0.7) 2 (0.5) 
Mean age at enrollment, yr (SD) 56.5 (9.0) 60.4 (8.6) 57.8 (9.1) 
Mean age at diagnosis, yr (SD) 59.6 (9.1) 62.8 (8.7) 60.6 (9.1) 
Median observed duration of disease 
among those who died, yr (range) 
0.50  
(0.003-8.61) 
0.54  
(0.01-5.4) 
0.52  
(0.003-8.61) 
Median observed duration of disease 
among those alive at last follow-up, yr 
(range) 
3.8 (1.5-8.2) 4.0 (1.5-7.7) 3.5 (1.5-8.2) 
Highest education level, yr    
       <12 134 (47.2) 48 (34.8) 182 (43.1) 
       ≥12 150 (52.8) 90 (65.2) 240 (56.9) 
       Unknown 2 1 3 
Household income in last year    
       <$15,000 190 (67.6) 87 (64.0) 277 (66.4) 
       ≥$15,000 91 (32.4) 49 (36.0) 140 (33.6) 
       Unknown 5 3 8 
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Table 3 Continued. Descriptive characteristics by race of incident non-small cell lung 
cancer (NSCLC) cases in the Southern Community Cohort Study.  
Smoking status at cohort entry    
       Current 206 (72.8) 93 (68.4) 299 (71.4) 
       Former 59 (20.8) 37 (27.2) 96 (22.9) 
       Never 18 (6.4) 6 (4.4) 24 (5.7) 
       Unknown 3 3 6 
Mean cigarettes per day (SD) 15.7 (13.1) 23.2 (14.7) 18.1 (14.1) 
Smokes menthol cigarettes    
       Yes 182 (69.2) 23 (17.8) 205 (52.3) 
       No 81 (30.8) 106 (82.2) 187 (47.7) 
       Unknown 23 10 33 
Self-reported doctor diagnosis of 
emphysema or chronic bronchitis 
   
       Yes 28 (9.9) 41 (29.7) 69 (16.4) 
       No 255 (90.1) 97 (70.3) 352 (83.6) 
       Unknown 3 1 4 
First-degree relative with lung cancer    
       Yes 21 (9.3) 26 (22.6) 47 (13.8) 
       No 205 (90.7) 89 (77.4) 294 (86.2) 
       Unknown 60 24 84 
Mean BMI, kg/m2 (SD) 26.8 (6.1) 27.1 (6.0) 26.9 (6.1) 
Health insurance status    
       Yes 174 (61.7) 98 (71.5) 272 (64.9) 
       No 108 (38.3) 39 (28.5) 147 (35.1) 
      Unknown 4 2 6 
Enrollment source    
       Community Health Center 268 (93.7) 113 (81.3) 381 (89.6) 
       General Population 18 (6.3) 26 (18.7) 44 (10.4) 
NOS=Not otherwise specified 
Yr=Year 
SD=Standard deviation 
BMI=Body mass index 
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Table 4. Average time-dependent AUCs for Cox proportional hazards models in the 
Southern Community Cohort Study 
Model Average time-dependent AUC 
African ancestry only (unadjusted) 0.54 
Main effectsa 0.79 
Interactionsb 0.83 
Main effects without African ancestry  0.79 
Interactions without African ancestry  0.82 
Main effects without stage and treatment 0.65 
Main effects without stage, treatment, and African ancestry  0.63 
aMain effects model is a Cox proportional hazards model examining association between African 
ancestry and lung cancer survival, adjusting for age at diagnosis, sex, BMI (kg/m2), cigarettes per 
day, stage at diagnosis, treatment, highest education level, and family history of lung cancer. 
bInteraction model is a Cox proportional hazards model examining association between African 
ancestry and lung cancer survival, adjusting for the same variables in the main effects model but 
also including the following two-way interactions (percent African ancestry x treatment, African 
ancestry x stage, African ancestry x education, education x treatment, education x stage, 
treatment x stage, sex x age, sex x BMI, sex x cigarettes per day). 
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Table 5. Average time-dependent AUCs for each Cox proportional hazards model among 
black non-small cell lung cancer cases from the Southern Community Cohort Study 
(SCCS) and Wayne State University (WSU). 
 Average time-dependent AUC 
Model SCCS blacks WSU 
African ancestry only 0.53 0.53 
Main effects1 0.82 0.75 
Interactions2 0.85 0.80 
Main effects without African ancestry  0.81 0.74 
Interactions without African ancestry  0.83 0.76 
Main effects without stage and treatment 0.67 0.63 
Main effects without stage, treatment, and African ancestry 0.67 0.61 
Main effects model is a Cox proportional hazards model examining association between African 
ancestry and lung cancer survival, adjusting for age at diagnosis, sex, BMI (kg/m2), cigarettes per 
day, stage at diagnosis, treatment, highest education level, and family history of lung cancer. 
Interaction model is a Cox proportional hazards model examining association between African 
ancestry and lung cancer survival, adjusting for the same variables in the main effects model but 
also including the following two-way interactions (percent African ancestry x treatment, African 
ancestry x stage, African ancestry x education, education x treatment, education x stage, 
treatment x stage, sex x age, sex x BMI, sex x cigarettes per day). 
 
  
! 47 
Table 6. Descriptive characteristics of non-small cell lung cancer (NSCLC) cases from the 
Karmanos Cancer Institute/Wayne State University (KCI/WSU). 
 Blacks  
(N=316) 
N (%) 
Sex  
       Male 129 (40.8) 
       Female 187 (59.2) 
Vital status  
       Alive 107 (33.9) 
       Dead 209 (66.1) 
Median African ancestry, % (range) 83.3 (33.6-100.0) 
Lung cancer stage at diagnosis  
       I 107 (34.3) 
       II/III 123 (39.4) 
       IV 82 (26.3) 
       Unknown 4 
Treatment  
       No treatment 27 (8.5) 
       Surgery only 85 (26.9) 
       Chemotherapy only 32 (10.1) 
       Radiation only 26 (8.2) 
       Multi-modality 146 (46.2) 
Histology  
       Adenocarcinoma 159 (50.3) 
       NSCLC-NOS 79 (25.0) 
       Squamous 71 (22.5) 
       Other  7 (2.2) 
Mean age at diagnosis, yr (SD) 60.3 (11.02) 
Median observed duration of disease among those who died, yr 
(range) 
2.1 (0.33-11.5) 
Median observed duration of disease among those alive at last 
follow-up, yr (range) 
6.5 (3.8-13.7) 
Highest education level, yr  
       <12 89 (28.2) 
       ≥12 227 (71.8) 
Smoking status at cohort entry  
       Current 177 (56.0) 
       Former 123 (38.9) 
       Never 16 (5.1) 
       Unknown 0 
Mean cigarettes per day (SD) 18.3 (13.3) 
First-degree relative with lung cancer  
       Yes 62 (19.6) 
       No 254 (80.4) 
Mean BMI, kg/m2 (SD) 26.6 (6.6) 
NOS=Not otherwise specified, Yr=Year, SD=Standard deviation, BMI=Body mass index  
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 Table 7. Average time-dependent AUCs for Cox proportional hazards models in the 
combined SCCS and KCI/WSU population 
Model Average time-dependent AUC 
African ancestry only (unadjusted) 0.55 
Main effectsa 0.80 
Interactionsb 0.85 
Main effects without African ancestry  0.80 
Interactions without African ancestry  0.85 
Main effects without stage and treatment 0.63 
Main effects without stage, treatment, and African ancestry  0.61 
aMain effects model is a Cox proportional hazards model examining association between African 
ancestry and lung cancer survival, adjusting for age at diagnosis, sex, BMI (kg/m2), cigarettes per 
day, stage at diagnosis, treatment, highest education level, and family history of lung cancer. 
bInteraction model is a Cox proportional hazards model examining association between African 
ancestry and lung cancer survival, adjusting for the same variables in the main effects model but 
also including the following two-way interactions (percent African ancestry x treatment, African 
ancestry x stage, African ancestry x education, education x treatment, education x stage, 
treatment x stage, sex x age, sex x BMI, sex x cigarettes per day).  
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Figure 7. Distribution of stage (A) and treatment (B) for blacks and whites in the Southern 
Community Cohort Study (SCCS) and blacks in the Karmanos Cancer 
Institute(KCI)/Wayne State University (WSU) studies. 
  
A 
B 
! 50 
!
Figure 8. Genetic ancestry estimates for blacks (N=286) and whites (N=139) with non-small 
cell lung cancer in the Southern Community Cohort Study. 
Global ancestry was estimated using ADMIXTURE software and ancestry informative markers 
(N=1137 in blacks and N=553 in whites) using a supervised method including CEU (European) 
and YRI (African) reference populations from the International HapMap Project. Individuals are 
plotted along the x-axis and along the y-axis is the percent African ancestry (dark blue) and 
percent European ancestry (light blue) for each individual. 
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Figure 9. African ancestry is not associated with lung cancer survival, with or without stage 
and treatment included in the model. 
Hazard ratios and 95% confidence intervals are plotted on the y-axis for the association between 
splined percent African ancestry (x-axis) and lung cancer survival in the Southern Community 
Cohort Study for the (A) main effects model and the (B) main effects model without stage and 
treatment (see Methods). Median African ancestry (80%) is the referent (vertical grey line).  
Main effects model is a Cox proportional hazards model examining the association between 
African ancestry and lung cancer survival, adjusting for age at diagnosis, sex, BMI (kg/m2), 
cigarettes per day, stage at diagnosis, treatment, highest education level, and family history of 
lung cancer.  
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Figure 10. Time-dependent AUCs for each Cox proportional hazards model in the 
Southern Community Cohort Study. 
Removal of stage and treatment, not African ancestry, resulted in a reduction in the predictive 
ability of the main effects model. African ancestry had no effect on the time-dependent AUC of 
the main effects model, with or without stage and treatment. 
!The Kaplan-Meier survival probability estimates below the x-axis represent the probability of 
surviving to the indicated 6 month intervals as estimated from the main effects model (black) and 
from the main effects model without stage or treatment (blue).  
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Figure 11. Time-dependent AUCs for each Cox proportional hazards model among self-
reported blacks in the Southern Community Cohort Study (SCCS). 
The Kaplan-Meier survival probability estimates below the x-axis are the represent the 
probability of surviving to the indicated 6 month intervals as estimated from the main effects 
model (black) and from the main effects model without stage or treatment (blue).  
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Figure 12. Genetic ancestry estimates for non-small cell lung cancer cases in the Karmanos 
Cancer Institute/Wayne State University study population (N=316). 
Global ancestry was estimated using ADMIXTURE software and genome-wide single nucleotide 
polymorphisms in a supervised manor using CEU (European) and YRI (African) reference 
populations from the International HapMap Project. Individuals are plotted along the x-axis and 
along the y-axis is the percent African ancestry (dark blue) and percent European ancestry (light 
blue) for each individual. 
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Figure 13. Time-dependent AUCs for each Cox proportional hazards model among black 
non-small cell lung cancer cases in the Karmanos Cancer Institute/Wayne State University 
study population. 
The Kaplan-Meier survival probability estimates below the x-axis are the represent the 
probability of surviving to the indicated 6 month intervals as estimated from the main effects 
model (black) and from the main effects model without stage or treatment (blue). 
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Figure 14. Time-dependent AUCs for each Cox proportional hazards model in the 
combined SCCS and KCI/WSU population. 
The Kaplan-Meier survival probability estimates below the x-axis are the represent the 
probability of surviving to the indicated 6 month intervals as estimated from the main effects 
model (black) and from the main effects model without stage or treatment (blue). 
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CHAPTER 3 
 
GERMLINE GENETIC VARIANTS AND LUNG CANCER SURVIVAL IN AFRICAN 
AMERICANS1 
 
Introduction 
Epidemiology of lung cancer survival 
 Lung cancer is the leading cause of cancer-related death in the United States (American 
Cancer Society 2017). Notably African Americans have poorer lung cancer survival compared to 
whites, namely a 16% 5-year survival in African Americans compared to 19% in whites 
(Howlader N). This poor survival can largely be attributed to presentation at a later stage in 
African Americans, which is associated with reduced lung cancer survival (Efird et al. 2014). In 
the clinical setting, an individual’s treatment plan is tailored to the stage of lung cancer diagnosis 
and can impact lung cancer survival (National Comprehensive Cancer Network 2017). Other 
factors associated with poor lung cancer survival include low socioeconomic status (SES), 
smoking, older age, male sex, site of origin, tumor grade, histologic subtype and somatic 
mutation profile (William D. Travis 2004, Islami et al. 2015).  
 
 
 !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
1 Adapted from: Jones, C. C., W. S. Bush, D. C. Crawford, A. S. Wenzlaff, A. G. Schwartz, J. K. 
Wiencke, M. R. Wrensch, W. J. Blot, S. J. Chanock, E. L. Grogan and M. C. Aldrich (2017). "Germline 
genetic variants and lung cancer survival in African Americans." Cancer Epidemiol Biomarkers Prev. !
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Genetic studies of lung cancer survival 
Tumor mutation status is frequently incorporated into genetic medicine to guide 
therapeutic decisions (Pao et al. 2005, Pao and Chmielecki 2010). However, germline variation 
could also influence treatment response (Bell et al. 2005, Gregorc et al. 2008). Genetic 
association studies have successfully identified germline variants that contribute to lung cancer 
survival, but genome-wide association studies (GWAS) of lung cancer survival have been 
conducted only in populations of European or Asian descent (Wu et al. 2010, Sato et al. 2011, 
Tan et al. 2011, Wu et al. 2011, Hu et al. 2012, Lee et al. 2013, Wu et al. 2013, Han et al. 2014). 
To improve the precision of approaches based on population genetic history, genetic studies in 
diverse racial/ethnic populations need to be conducted. Overall, African descent populations 
have shorter segments of linkage disequilibrium compared to European descent populations, thus 
examining genetic associations of disease in African American populations may allow for 
improved fine mapping of causal variants with potential therapeutic benefits applicable across 
racial/ethnic groups. 
 
Rationale 
 Using a prospective cohort of African Americans, we sought to validate lung cancer 
survival variants previously reported in the National Human Genome Research Institute GWAS 
catalog (Burdett T (EBI)), accounting for known factors influencing survival. We also sought to 
identify novel and potentially functional genome-wide germline variants associated with lung 
cancer survival in African Americans. Though the present study is underpowered to detect 
genome-wide associations, this is the first study to our knowledge to examine genome-wide 
germline genetic associations of lung cancer survival in African Americans. 
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Methods 
Southern Community Cohort Study 
The Southern Community Cohort Study (SCCS) is a large prospective cohort study of 
~86,000 individuals designed to examine racial disparities in cancer. Adults between the ages of 
40-79 years were enrolled primarily at community health centers throughout a 12-state region 
across the Southeastern United States (Alabama, Arkansas, Florida, Georgia, Kentucky, 
Louisiana, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, and West Virginia) 
between March 2002 and September 2009. Approximately 90% of enrolled individuals agreed to 
donate a biologic specimen. Nearly two-thirds of participants self-identified as African 
American. Additional details regarding the study design and recruitment have been previously 
published (Signorello et al. 2005, Signorello et al. 2010). The SCCS was approved by 
Institutional Review Boards at Vanderbilt University and Meharry Medical College. Written 
informed consent was obtained from all participants. 
 
Case identification and mortality assessment 
Incident African American lung cancer cases occurring in the SCCS through September 
2012 were identified via linkage with the 12 state cancer registries throughout the study 
catchment area. Epidemiologic data such as demographic characteristics, self-reported medical 
history, and tobacco use, were ascertained at study enrollment by trained personnel via in-person 
computer-assisted interviews at community health centers or by questionnaire mailed to a 
random subset of the general population in the 12-state region (Signorello et al. 2005, Signorello 
et al. 2010). Histology, stage at diagnosis, and clinical treatment were collected from state cancer 
registry data. Lung cancer stage was determined using the American Joint Committee on Cancers 
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(AJCC) staging system and Surveillance, Epidemiology, and End Results (SEER) summary 
stage. Treatment information was identified from cancer registries and summarized as a 5-level 
design variable: no treatment, chemotherapy only, radiation only, surgery only, or multi-
modality (any combination of the above therapy regimens). Participants were followed for all-
cause mortality through 2013, which was assessed via linkage with the Social Security 
Administration and the National Death Index. Survival time (years) was defined as the time 
between date of diagnosis and date of death, loss to follow-up, or end of follow-up period for the 
study. 
 
Genotyping and quality control 
 Individuals with an available blood or buccal cell biospecimen from which germline 
DNA could be extracted as of September 2012 were genotyped on the Illumina HumanExome 
BeadChip v1.1 (San Diego, CA). The HumanExome genotyping array contains >240,000 exonic 
variants, as well as a panel of >3,000 Ancestry Informative Markers (AIMs) for distinguishing 
African and European ancestries, and >4,700 disease-associated tag markers identified from 
GWAS. A detailed description of the quality control (QC) process is presented in Figure 15. 
Briefly, QC procedures removed individuals having mismatched genetic sex, <98% genotyping 
efficiency and related individuals. Autosomal variants were excluded that had Mendelian errors, 
a call rate <98% or were monomorphic. A total of 14 samples were used to verify genotype 
reproducibility, with a genotype concordance of >99.99%. Analysis of previous lung cancer 
survival associations from the NHGRI-EBI GWAS catalog and common variants was restricted 
to variants with a minor allele frequency (MAF) >5%. QC filters were applied using PLINK and 
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R (version 3.0.3) (Purcell et al. 2007). Variants were mapped to dpSNP Build 137/GRCH37.p5 
based on chromosome and position to obtain reference SNP (rs) identifiers. 
 
Admixture estimation 
 Global ancestry was estimated using the ADMIXTURE software (Alexander et al. 2009). 
The CEU (Utah residents with ancestry from northern and western Europe) and YRI (Yoruba 
from Ibadan, Nigeria) HapMap populations were included as ancestral reference populations to 
inform the admixture estimation process (International HapMap Consortium 2003).!After 
merging with the HapMap reference populations and pruning based on linkage disequilibrium 
(r2>0.4), 1,137 AIMs remained among the 2,587 AIMs in the final QC dataset for estimation of 
genetic admixture. Supervised (k=2) admixture analysis was performed to estimate the percent 
African (YRI) and European (CEU) ancestry for each African American individual. 
 
Statistical Analysis 
Replication of Lung Cancer Survival Variants from the NHGRI-EBI GWAS Catalog 
 Variants previously associated with lung cancer survival and genotyped on the 
ExomeChip (MAF ≥ 5%) were identified from the NHGRI-EBI GWAS catalog (rs1878022, 
rs1209950, rs9981861, rs1656402, and rs716274, Table 8) (Burdett T (EBI)). For each additively 
coded variant, we ran a Cox proportional hazards model, controlling for age at diagnosis, sex, 
disease stage, treatment, and percent African ancestry. Statistical significance was determined 
using Bonferroni correction based on the number of a priori variants tested (five variants, 
α=0.05/5=0.01). We also examined whether smoking pack-years, education, and self-reported 
! 62 
COPD status modified our genetic associations. All statistical analyses were conducted using the 
R survival package (survival, version 2.37-7). 
 
Discovery of novel common associations 
 Cox proportional hazards models were used to estimate hazard ratios assessing the 
association between common (MAF ≥ 5%) variants and lung cancer survival. Genotypes were 
coded additively and models were adjusted for age at diagnosis, sex, disease stage, treatment, 
and percent African ancestry. We further adjusted our models to assess the impact of smoking, 
education, and self-reported COPD status on our genetic associations. Functional predictions 
were conducted using PolyPhen-2 and SIFT gathered from the ENSEMBL website (Kumar et al. 
2009, Adzhubei et al. 2010). A Bonferroni-corrected type I error rate of α=0.05/28,041 variants 
= 1.78x10-6 was set for inference of statistical ‘significance’. For comparison, the number of 
unique tests was calculated using simpleM (Gao et al. 2008, Gao et al. 2010) and a secondary 
type I error rate was examined.  
 
Rare variant analysis 
 Survival analysis of rare variants was conducted using the seqMeta of R (version 1.5). 
We examined the association of variants with lung cancer survival using both the sequence 
kernel association test (SKAT) and burden test. Both tests perform gene-level association tests 
by collapsing variants into predefined regions. For the present study, variants were aggregated 
into gene regions based on hg 19 transcription start and stop sites. Variants that did not map to 
gene boundaries were excluded from analysis. For the SKAT, variants within each gene region 
are weighted based on their minor allele frequency, while the burden test assumes a constant 
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weight for all variants. Both tests were performed for all variants and for variants with a MAF < 
5%.  Cox proportional hazards models were adjusted for age, sex, and percent African ancestry.  
 
Replication 
Two independent African American lung cancer study populations were available for 
replication of common variants: 1) the Karmanos Cancer Institute (KCI) at Wayne State 
University (WSU) and 2) University of California San Francisco (UCSF). Non-small cell lung 
cancer cases from both study populations (N=316 and N=298, respectively) were previously 
genotyped on the Illumina HumanHap 1M Duo array (San Diego, CA) and filtered based on 
standard quality control measures. Four variants meeting our p-value threshold for replication 
that were not directly genotyped were imputed with IMPUTE2 using a cosmopolitan reference 
population from 1000 Genomes (phase 1, b37, June 2014 release), with phasing performed using 
SHAPEIT (Howie et al. 2009). KCI/WSU African American lung cancer cases were included 
from three WSU studies: the Family Health Study (FHS study III), the Women’s Epidemiology 
of Lung Disease (WELD) Study, and the EXHALE (Exploring Health, Ancestry and Lung 
Epidemiology) Study, and have been previously described (Schwartz et al. 2009). Cases were 
ascertained using rapid case ascertainment through the population-based Metropolitan Detroit 
Cancer Surveillance System, an NCI-funded SEER registry. Stage, treatment, and vital status 
were ascertained from the Detroit SEER registry. African Americans participating in the UCSF 
lung cancer study were identified using rapid case ascertainment methods from September 1998 
to March 2003 (Wrensch et al. 2005). Specifically, cancer histology and stage were determined 
using ICD-O codes abstracted from SEER data from the California Cancer Registry (CCR). The 
CCR also provided data for whether surgery, radiation, and chemotherapy were given to the 
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patients, their last known vital status, and date of death or date of last contact. Stage and 
treatment information for both replication populations were summarized using the same 
algorithm as implemented within the SCCS. Percent African ancestry was estimated using 
genome-wide data and a supervised analysis (k=2) implemented with ADMIXTURE (Alexander 
et al. 2009). A fixed effects meta-analysis of the discovery (SCCS) and replication (KCI/WSU 
and UCSF) cohorts was performed using METAL (Willer et al. 2010). 
One variant, rs1878022, was also examined in a population of self-reported whites from 
the SCCS. Incident lung cancer cases were identified and genotyped in the same manner as 
described for African Americans. In total, 129 white incident lung cancer cases met quality 
control criteria and were included in the analysis. 
 
Results 
Descriptive Characteristics 
Using linkage with the state cancer registries, we identified a total of 336 incident 
African American lung cancer cases in the SCCS cohort with an available biospecimen.  After 
implementation of QC procedures, 286 African Americans with non-small cell lung cancer 
(NSCLC) were included in our study (Figure 15). The mean follow-up time was 1.3 years 
(min=0.003, max=8.6), and 87% of individuals were deceased at the end of follow-up. Lung 
cancer cases were diagnosed at a mean age of 60 years and were primarily (60%) male (Table 9).  
Ninety-four percent of individuals were recruited from community health centers resulting in a 
primarily low socioeconomic status (SES) population with 68% having an annual household 
income less than $15,000, and nearly half (47%) of participants had less than a high school 
education. Fifty-two percent of African American lung cancer cases in the SCCS were diagnosed 
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with stage IV disease (Table 9, Figure 16). Median African ancestry was 86% (Figure 17A) 
among SCCS African American non-small cell lung cancer cases. African American NSCLC 
cases in the KCI/WSU (N=316) and UCSF (N=298) studies had lower African ancestry (83% 
and 82%, respectively; Figure 17B and Figure 17C), higher SES and fewer stage IV diagnoses 
(26% KCI/WSU and 29% UCSF; Table 10 and Figure 16) than African Americans in the SCCS. 
The mean follow-up time for the KCI/WSU and UCSF populations was 4.0 years (min=0.3, 
max=13.7) and 2.8 years (min=0.2, max=9.0), respectively.  Our final sample size for complete 
case analysis was N=275 in the SCCS, N=312 in KCI/WSU, and N=284 in UCSF. 
 
NHGRI-EBI GWAS Catalog Variants 
Of the variants previously associated with lung cancer survival in the NHGRI-EBI 
GWAS Catalog, only five were genotyped on the Illumina HumanExome BeadChip and passed 
quality control metric (Wu et al. 2010, Sato et al. 2011, Wu et al. 2011). Variants rs1209950, 
rs9981861, rs1656402, and rs716274 were previously identified in East Asian populations, while 
rs1878022 was previously reported in a European descent population (Table 8 and Table 11). 
Variants had similar allele frequencies as those observed in the 1000 Genomes Americans of 
African Ancestry in the Southwestern US (ASW) population (Table 11). We observed that the C 
allele for rs1878022 in the CMKLR1 gene was significantly associated with lower mortality after 
correction for multiple testing (Hazard Ratio, HR = 0.70, 95% Confidence Interval (CI): 0.54-
0.92), adjusting for age, sex, stage, treatment, and African ancestry (Table 13). Though hazard 
ratios were in the same direction as previously reported for the remaining four variants, 
confidence intervals were wide and results were not significantly associated with lung cancer 
survival in our SCCS discovery population of African Americans. Inclusion of pack years, 
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education, and self-reported COPD status in our Cox proportional hazards models did not 
appreciably alter (<10% change) our genetic associations (Table 12). Associations of rs1878022 
in the KCI/WSU and UCSF study populations had hazard ratios in the same direction as the 
SCCS, although not statistically significant (KCI/WSU: HR = 0.87, 95% CI: 0.66-1.14; UCSF: 
HR = 0.94, 95% CI: 0.72-1.24, Table 12). A fixed effects meta-analysis of the three populations 
revealed a summary hazard ratio of 0.83 (95% CI: 0.71-0.97, p = 0.02, I2=0.30, Figure 18). 
Stratification of the SCCS cohort by stage revealed a significant association among African 
Americans with stage IV lung cancer (HR = 0.62, 95% CI: 0.44-0.88, p = 0.008, Table 14). 
Pooled analysis of stage IV individuals from KCI/WSU and UCSF resulted in a HR of 1.22 
(95% CI: 0.86-1.72, Table 14) and a stage-stratified meta-analysis of the three populations 
(N=308) found an attenuated and non-significant association among stage IV individuals (HR = 
0.83, 95% CI: 0.65-1.07). Genotype frequencies and ancestry estimates by study population and 
stage at diagnosis are presented in Table 15 and Table 16, respectively. 
Since the C allele at rs1878022 was previously associated with increased lung cancer 
mortality in a European-descent population (Wu et al. 2011), we also examined the effects of 
rs1878022 in a population of whites from the SCCS. In total, 129 white incident NSCLC cases 
passed quality control and were included in our analysis. While the hazard ratio was reduced 
(HR=0.88), the confidence intervals were wide (95% CI=0.64-1.19), providing no for an 
association between rs1878022 and lung cancer survival in whites. 
 
ExomeChip Common Variant Associations 
We examined common variants associated with lung cancer survival among African 
Americans. After quality control, 28,041 common variants remained for analysis, of which 
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simpleM identified 23,653 unique tests. No variant was considered significant based on a 
Bonferroni correction for the number of tests (N=28,041) or for the number of unique tests 
(N=23,653). However, thirteen variants had p-values < 1.0x10-4, Table 17 and Figure 19. Of the 
13 variants with the smallest p-values, seven were associated with greater all-cause mortality and 
six were associated with reduced all-cause mortality in additive models with increasing copies of 
the minor allele. All SNPs had similar allele frequencies to those observed in the 1000 Genomes 
ASW reference population (Table 18). SNP rs1133358, a variant in the SUN5 gene on 
chromosome 20q11, was the most strongly associated with mortality (HR = 0.61, 95% CI: 0.49-
0.76) and predicted by SIFT to be deleterious to protein function, though with low confidence 
(Table 17 and Table 19). Four of the 13 variants (rs2072633, rs1505229, rs7502216, rs537160) 
were located within gene introns and an additional five (rs1133358, rs8176785, rs7626962, 
rs35761244, rs1639122) were exonic. SNP rs7626962 was also predicted to have deleterious 
effects by SIFT (Table 19).  A peak on chromosome 6p21.33 revealed three variants (rs605203, 
rs2072633, rs537160, r2 < 0.5) associated with reduced mortality (HR=0.46, 95% CI: 0.33-0.66; 
HR=0.66, 95% CI: 0.54-0.81; HR=0.61, 95% CI: 0.48-0.78, respectively). Conditional analysis, 
which examined all two- and three-way combinations of the three SNPs at chromosome 6p21.33, 
identified no single variant solely responsible for the association at this locus. P-values were 
attenuated for all variants; however, rs605203 remained consistently significant (Table 20). 
Since the three reported SNPs are in relatively weak LD (r2<0.5) with each other it is 
unsurprising that conditional analysis did not reveal the ‘causal’ signal. We hypothesize that all 
three variants are in LD with the true causal variant, which is driving the observed association of 
these three variants in the present analysis.  
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  Adding smoking pack-years, education, and self-reported COPD status to our statistical 
models did not substantially alter the observed hazard ratios (Table 21). We further examined 
these 13 variants in our KCI/WSU and UCSF replication populations (Table 17). Within the 
KCI/WSU study population, the G allele at rs7302017 was associated with increased mortality 
(HR: 1.29, 95% CI: 1.01-1.63), while the G allele at rs605203 was associated with reduced 
mortality in the UCSF study population (HR: 0.55, 95% CI: 0.38-0.78). Both of these 
associations have the same magnitude and direction of effect as the discovery cohort. 
 
Rare Variant Analysis 
 After quality control, 85,018 variants, including 62,077 with MAF < 5%, mapped to gene 
boundaries and were non-monomorphic in the final testing population of 275 African Americans 
with incident NSCLC. A total of 15,279 genes were examined by both the SKAT and burden test 
when no restriction based on MAF was applied. The mean number of variants per gene was 5.6, 
with a maximum of 341. When analysis was restricted to rare variants (MAF <5%), 14,015 genes 
were tested, with the mean of 4.4 SNPs per gene (max. 283). The distribution of the number of 
variants per gene is presented in Figure 20. Cumulative allele frequencies of all variants within a 
gene region ranged from 0.0018 to 16.04 (median=0.1855) when all variants were examined and 
0.0018 to 2.075 (median=0.0255) when the variants were restricted to those with a MAF<5%. 
 Gene-level SKAT results for all variants and for variants with a MAF<5% are presented 
in Figure 21 and Figure 22, respectively. No gene surpassed a Bonferroni corrected significance 
threshold and restriction based on MAF did not drastically alter the results, with eight of the ten 
most significant genes identified in both analyses. Burden tests results for all variants and for 
variants with a MAF<5% are presented in Figure 23 and Figure 24. There was substantially less 
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consistency between burden tests results with and without restriction based on MAF, with only 
three genes identified in both analyses. The burden test inclusive of all variants identified one 
gene, PLIN3, surpassing a Bonferroni significance p-value threshold (p=7.5x10-7, HR=0.65, 95% 
CI: 0.55-0.77). Restriction to rare variants reduced the cumulative allele frequency from 0.46 to 
0.02 and resulted a near complete attenuation of the signal at PLIN3 (p=0.04).  
 
Discussion 
We sought to validate lung cancer survival variants previously identified in Asian or 
European populations in an incident study of African Americans. We additionally sought to 
identify novel common variants associated with lung cancer survival in African Americans and 
performed a preliminary examination of rare variants. Our evaluation of five previously 
identified lung cancer survival GWAS SNPs identified one variant in the CMKLR1 gene 
significantly associated with reduced mortality in African Americans with NSCLC. The 
remaining four variants were not significantly associated. The observed reduced mortality for 
rs1878022 is in contrast to a prior study by Wu and colleagues conducted in European 
Americans in which they reported that the minor allele of rs1878022 was associated with 
increased mortality (Wu et al. 2011). All individuals in the study by Wu et al. were white ever-
smokers with stage III or IV NSCLC who received platinum-based chemotherapy and no 
surgery; whereas, in the present study of African Americans no restriction was made on stage, 
treatment, or smoking status for study inclusion. Our analysis of white incident cases from the 
SCCS revealed no significant association between rs1878022 and survival. Given the reduced 
power resulting from our small population of whites, we are unable to verify the population 
specific effects. Of note, the frequency of the C allele in the 1000 Genomes populations differs 
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between European and African populations (35% versus 13%). The observed allele frequency of 
14% in the present study of SCCS African Americans is similar to the reported frequency (18%) 
in the 1000 Genomes African American (ASW) population and in the UCSF and WSU lung 
cancer cases (17.4% and 18.8%, respectively). While the observed population-specific effects of 
rs1878022 may simply be the result of a spurious association, it could also result from 
differences in linkage disequilibrium (LD) patterns between Africans and Europeans as a 
reflection of distinct backbone haplotypes that could have different causal variants. Examination 
of LD structure surrounding the CMKLR1 gene revealed differences between the YRI and CEU 
populations, with the CEU having larger blocks of strong LD (Figure 25). Using LDlink 
(Machiela and Chanock 2015) and  data from an African (YRI) population, we find five variants 
are in strong LD with rs1878022 (r2>0.8) and an additional eight variants in moderate LD (r2>0.3 
and r2 < 0.8) while six variants are in moderate LD in whites (CEU) and none in strong LD. 
RegulomeDB (Boyle et al. 2012) reveals two of the variants in moderate LD in the YRI 
(rs4964244 and rs4964245, r2=0.44 and 0.38, respectively) and one variant in the CEU 
(rs4964242, r2=0.55) have high regulatory potential and are likely to affect binding. Variant 
rs4964242 is not in LD with rs4964244 or rs4964245 in either the CEU or YRI population 
(r2≤0.1), indicating that different regulatory variants could account for the observed population-
specific effects. It is possible that rs1878022 is tagging a different causal variant in the YRI 
population than in the CEU population and thus it remains necessary to fine map the CMKLR1 
gene to determine the causal variant influencing lung cancer survival in African Americans 
compared to European Americans.  
SNP rs1878022 is located within the second intron within the 5’-untranslated region of 
the chemokine-like receptor 1 (CMKLR1) gene on chromosome 12q23.3. CMKLR1 encodes a 
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seven transmembrane G-protein coupled receptor that has been associated with adiposity, 
glucose intolerance, and inflammation (Rama et al. 2011, Ernst et al. 2012). It has also been 
shown to play a role in the immune response to cigarette smoke in murine models of chronic 
obstructive pulmonary disease, an established risk factor for lung cancer risk (Demoor et al. 
2011). Furthermore, in response to binding of its ligand, chemerin, CMKLR1 has been shown to 
activate MAPK, ERK1/2, and Akt signaling cascades involved in cell cycle regulation (Kaur et 
al. 2010). Examination of ENCODE data at rs1878022 identified a small peak of H3K27Ac and 
H3K4me1 in normal human lung fibroblasts (Figure 26). Epigenetic markers found surrounding 
rs1878022 are commonly found at active regulatory elements and suggest that this variant might 
play a role in the regulation of CMKLR1 activity.  
It is important to note that the present analyses were limited by the design of the 
genotyping array used in the discovery population. The Illumina HumanExome BeadChip was 
designed to capture biologically-relevant coding variation. As a result, variants were not evenly 
distributed across the genome and were predominantly rare in frequency (MAF < 5%). This 
array also includes >4,500 variants identified in recent genome-wide association studies. 
However, while there were >20 variants associated with lung cancer survival in the NHGRI-EBI 
GWAS catalog at the time of our data extraction, only 5 were present on the genotyping array for 
examination in the current study. This discrepancy correlates with the date variants were 
deposited into the NHGRI-EBI GWAS Catalog verses the creation of the array. Furthermore, the 
unique design of the exome array precluded us from analyzing variants in LD with the five 
previously reported variants examined here. Examination of LD patterns surrounding the five 
NHGRI-EBI GWAS variants in the relevant 1000 Genomes reference population revealed four 
variants in LD (+/-100 kb, r2>0.6, CEU reference population) with rs1878022, the only variant 
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previously identified in a European descent population, and 57 variants in LD (+/-100 kb, r2>0.6, 
Han Chinese in Beijing, China (CHB) reference population) with one of the four variants 
identified in an Asian descent population; none of these variants were present on the exome 
array. Future analyses should perform a thorough examination of LD structure surrounding these 
variants and include present in the NHGRI-EBI GWAS catalog but not present here. 
While our analysis of common variants did not identify any significant variants, several 
variants had promising p-values for associations with mortality, including multiple protein 
coding variants. Three variants on chromosome 6p21.33 in weak LD (rs605203, rs2072633, and 
rs537160, r2<0.5) were associated with a reduction in mortality. All three variants were non-
protein coding. Variant rs605203, which had a similar hazard ratio in the UCSF population, is 
located 70bp upstream of the SLC44A4 gene and downstream of EHMT2. Variants rs2072633 
and rs537160 are located within the 29th and 19th intron of the complement factor B (CFB) gene, 
respectively. Chromosome 6p21.33 is part of the gene-rich human leukocyte antigen (HLA) 
region. The 6p22.1-p21.31 chromosome region has been previously associated with lung cancer 
risk in both European and African Americans, though these results have inconsistently replicated 
(Truong et al. 2010, Zhang et al. 2010, Bae et al. 2012, Timofeeva et al. 2012, Walsh et al. 
2013). Furthermore, rs4324798 located at 6p22.1 was previously associated with increased 
survival in a European descent population of never-smoking small cell lung cancer cases (Yang 
et al. 2010, Xun et al. 2011). Lung cancer susceptibility within this region has been largely 
attributed to the BAT3 and MSH5 genes, which play an important role in DNA damage response 
and potentially response to cancer therapeutics (Sasaki et al. 2007, Tompkins et al. 2009, Wu et 
al. 2013).!Our findings support an association of the 6p22.1-p21.33 region with overall survival 
in African American NSCLC cases.  
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We identified variant rs1639122 on chromosome 12, located within the chromodomain 
helicase DNA binding protein 4 (CHD4). A change from the A to C allele results in a missense 
mutation that changes the amino acid from glutamate to aspartate. CHD4 is involved in 
nucleosome remodeling and transcriptional silencing as part of the nucleosome remodeling and 
deacetylation (NuRD) complex (Tong et al. 1998, Xue et al. 1998). Additionally, CHD4 plays a 
role in DNA damage response and cell cycle progression (Polo et al. 2010, Smeenk et al. 2010). 
Somatic mutations in CHD4 were identified in endometrial tumors and a germline protein coding 
variant was associated with increased risk of overall cancer, malignant lymphoma, rectal cancer, 
and lung cancer, providing further evidence for a potential role of this gene in lung cancer 
survival (Le Gallo et al. 2012, Zhao et al. 2013, Yamada et al. 2015). While the majority of these 
common variants failed to replicate in the KCI/WSU and UCSF populations, the totality of 
evidence from previously published associations with lung cancer risk and biological plausibility 
suggest our findings should be further investigated in additional African American lung cancer 
populations.  
Analysis of rare variants utilized two common collapsing methods: the SKAT and burden 
test (Li and Leal 2008, Wu et al. 2011). Both tests attempt to increase statistical power by 
aggregating variants based on gene boundaries, which reduces the number of overall tests and 
increases the frequency of variation for a gene region. However, despite the employment of these 
methods we acknowledge that the present study is still underpowered to detect rare variant 
associations and, as such, the analysis of rare variants presented in this chapter is solely 
exploratory in nature. While the SKAT and burden test are both collapsing methods, the two 
tests differ in several key assumptions. Specifically, the burden test assumes that all variants 
within a gene region have the same magnitude and direction of effect. SKAT, on the other hand, 
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allows different effects for variants within the same gene region. Among all rare variant tests, 
only one gene was significantly associated with reduced mortality, PLIN3, though this 
association was most certainly driven by common variants, as the signal was almost completely 
attenuated upon restriction to rare variants (MAF<5%). PLIN3, or perilipin 3, is located on 
chromosome 19p13.3 and is involved in lipid oxidation in skeletal muscle (Covington et al. 
2015). PLIN3 has also been observed to be involved in endosomal localization of RAB9, a 
member of the RAS oncogene family (Aivazian et al. 2006). 
To our knowledge, this study is the first to examine genome-wide genetic variants 
associated with all-cause mortality among African American lung cancer cases. While we 
acknowledge our sample size is small, these analyses serve as a starting point for further 
investigation. With our limited sample size of African American lung cancer cases we have 
reduced statistical power to detect true associations and thus replication in a larger population of 
African American lung cancer cases is necessary. However, we had a priori evidence to assess 
variants previously associated with lung cancer survival, thus reducing the burden of multiple 
testing typical of genetic association studies.  Importantly, assessing trans-ethnic replication of 
the NHGRI-EBI GWAS Catalog lung cancer survival variants provides genetic information 
about lung cancer desperately needed among diverse racial/ethnic populations. Moreover, meta-
analysis of the discovery and replication cohorts provides additional support for this association. 
Our findings provide greater evidence of an association between the CMKLR1 gene and survival 
among lung cancer cases. 
While the two replication populations (KCI/WSU and UCSF) were similar, we note key 
differences between the discovery (SCCS) and replication study populations likely due to 
differences in the composition of the study base from which the lung cancer cases arose. The 
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discovery and the replication lung cancer cases were all sampled using cancer registries within 
primary study bases; however, the study base of the SCCS is defined by its prospective cohort 
design of primarily individuals seeking medical care at community health centers across the 
Southeastern United States and KCI/WSU and UCSF are defined by geographic regions 
encompassing the Detroit and the San Francisco Bay Area metropolitan areas, respectively. 
These different geographic samplings likely contributed to important differences across the three 
studies in education level, current smoking prevalence, and stage distribution. Specifically, a 
greater percentage of SCCS lung cancer cases were diagnosed at later stages of disease compared 
to KCI/WSU and UCSF cases (Figure 16). This difference in stage distribution between 
discovery and replication studies could be attributed to differences in cohort vs. case-control 
ascertainment since case-control designs often miss the sickest individuals. The observed 
difference in results across the discovery and replication studies among stage IV lung cancer 
cases for the association between rs1878022 and survival may be due to unique gene-
environment interactions or simply a matter of chance.  
 In summary, this study identified several variants associated with survival in African 
Americans lung cancer cases and controls, a high-risk and underrepresented population in lung 
cancer genetics research. By examining variants previously associated with lung cancer survival, 
we observed that rs1878022 is significantly associated with survival in African Americans. 
However, the direction of effect observed is in contrast to a previous study in Europeans, 
suggesting rs1878022 may have populations-specific effects on lung cancer survival due to 
possible differing causal variants between European descent populations and African Americans 
due to distinct LD substructure (Wu et al. 2011). Additionally, we identified several potential 
novel variants, both protein coding and non-coding, associated with survival in African 
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Americans, including a region on chromosome 6p21.33-p22.1 that has been previously 
associated with lung cancer risk and small cell lung cancer survival. Future studies fine-mapping 
CMKLR1 and the 6p21-22 region and conducting functional studies could lead to potential 
therapeutic interventions to improve lung cancer survival, especially in African Americans.   
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Table 8. Summary of the five previously reported lung cancer survival GWAS variants 
examined in the present study. 
SNP Study 
PubMed 
ID Population N 
Risk 
Allele HR 95% CI p value 
rs1878022 Wu X, et al. JNCI 2011 21483023 European 327 C 1.59 (1.32-1.92) 1.4x10-6 
rs1209950 Sato Y, et al. JTO 2010 21079520 East Asian 105 T 4.96 (2.52-9.76) 2.8x10-7 
rs9981861 Sato Y, et al. JTO 2010 21079520 East Asian 105 G 16.1 (5.38-51.2) 3.5x10-6 
rs1656402 Sato Y, et al. JTO 2010 21079520 East Asian 105 G 4.22 (2.32-7.66) 8.4x10-8 
rs716274 Wu C, et al. CR 2010 21118971 East Asian 245 G 1.92 (1.51-2.45) 1.3x10-7 
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Table 9. Descriptive characteristics of African Americans with incident non-small cell lung 
cancer participating in the Southern Community Cohort Study (N=286) 
 N (%) 
Sex  
       Male 171 (59.8) 
       Female 115 (40.2) 
Vital status  
       Alive 38 (13.3) 
       Dead 248 (86.7) 
Median African ancestry, % 85.6 
Lung cancer stage at diagnosis  
       I 44 (15.7) 
       II/III 90 (32.0) 
       IV 147 (52.3) 
       Unknown 5 
Treatment  
       No treatment 75 (26.8) 
       Surgery only 31 (11.1) 
       Chemotherapy only 51 (18.2) 
       Radiation only 36 (12.9) 
       Multi-modality 87 (31.1) 
       Unknown 6 
Histology  
       Adenocarcinoma 113 (39.5) 
       Non-small cell lung cancer-NOSa 78 (27.3) 
       Squamous 72 (25.2) 
       Other NSCLC 22 (7.7) 
       Multiple histologies 1 (0.3) 
Mean age at diagnosis, yr (SD) 59.6 (9.1) 
Mean duration of disease among those who died, yr (SD) 0.88 (1.1) 
Mean duration of disease among those alive at last follow-up, yr (SD) 4.1 (1.7) 
Highest education level, yr  
       <12 134 (47.2) 
       ≥12 150 (52.8) 
       Unknown 2 
Smoking status at cohort entry  
       Current 206 (72.8) 
       Former 59 (20.8) 
       Never 18 (6.4) 
       Unknown 3 
Mean cigarettes per day (SD) 15.7 (13.1) 
Mean smoking pack-years (SD) 37.5 (30.7) 
First-degree relative with lung cancer  
       Yes 21 (9.3) 
       No 205 (90.7) 
       Unknown 60 NOS!=!not!otherwise!specified;!SD!=!standard!deviation;!Yr!=!years! !
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Table 10. Descriptive characteristics of African Americans with NCSLC participating in 
the KCI/WSU and UCSF studies. 
 KCI/WSU 
(N=316) 
N (%) 
UCSF 
(N=298) 
N (%) 
Sex   
       Male 129 (40.8) 139 (46.6) 
       Female 187 (59.2) 159 (53.4) 
Vital status   
       Alive 107 (33.9) 102 (34.2) 
       Dead 209 (66.1) 196 (65.8) 
Median African ancestry, % 83.3 82.1 
Lung cancer stage at diagnosis   
       I 107 (34.3) 106 (37.7) 
       II/III 123 (39.4) 95 (33.5) 
       IV 82 (26.3) 83 (28.9) 
       Unknown 4 14 
Treatment   
       No treatment 27 (8.5) 37 (12.4) 
       Surgery only 85 (26.9) 89 (29.9) 
       Chemotherapy only 32 (10.1) 35 (11.7) 
       Radiation only 26 (8.2) 44 (14.8) 
       Multi-modality 146 (46.2) 93 (31.2) 
Histology   
       Adenocarcinoma 159 (50.3) 127 (42.6) 
       Non-small cell lung cancer-NOSa 79 (25.0) 74 (24.8) 
       Squamous 71 (22.5) 77 (25.8) 
       Other NSCLC 7 (2.2) 15 (5.0) 
       Multiple histologies  5 (1.7) 
Mean age at diagnosis, yr (SD) 60.3 (11.0) 63.1 (10.8) 
Mean duration of disease among those who died, yr (SD) 2.6 (1.8) 1.9 (1.6) 
Mean duration of disease among those alive at last follow-up, 
yr (SD) 
6.8 (2.1) 4.5 (2.4) 
Highest education level, yr   
       <12 89 (28.2) 72 (25.2) 
       ≥12 227 (71.8) 214 (74.8) 
       Unknown 0 12 
Smoking status    
       Current 177 (56.0) 95 (31.9) 
       Former 123 (38.9) 183 (61.4) 
       Never 16 (5.1) 20 (6.7) 
Mean cigarettes per day (SD) 18.4 (13.3) 20.5 (26) 
Mean smoking pack years (SD) 36.9 (28.6) 7.5 (15.2) 
First-degree relative with lung cancer   
       Yes 62 (19.6) 55 (18.5) 
       No 254 (80.4) 242 (81.5) 
       Unknown 0 1 
NOS = not otherwise specified; SD = standard deviation; Yr = years 
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Table 11. Allele frequency for the five variants previously associated with lung cancer 
survival in the NHGRI-EBI GWAS catalog in the SCCS (N=275), KCI/WSU (N=312), and 
UCSF (N=284) populations. Allele frequencies are also presented for the ASW 1000 
Genomes African American reference population and for the 1000 Genomes reference 
population that matches the racial/ethnic group of the original discovery population (CEU 
or CHB).  
SNP Allelea 
SCCS 
MAF 
KCI/WSU  
MAF 
UCSF 
MAF 
ASWb 
MAF 
Discovery GWAS  
population 
CEU/CHBb 
MAFc 
rs1878022 C/T 0.14 0.19 0.17 0.19 European 0.30 
rs1209950 T/C 0.14 0.14 0.16 0.16 East Asian 0.04 
rs9981861 G/A 0.29 0.35 0.35 0.34 East Asian 0.16 
rs1656402 A/G 0.42 0.41 0.36 0.39 East Asian 0.28 
rs716274 G/A 0.43 0.47 0.49 0.54 East Asian 0.20 
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Table 12. Multivariable Cox proportional hazards results for African Americans with incident non-small cell lung cancer and 
the five SNPs previously associated with lung cancer survival in the NHGRI-EBI GWAS catalog assayed by the Illumina 
HumanExome BeadChip v1.1. 
    SCCS (N=275)  KCI/WSU (N=312)  UCSF (N=284) 
SNP Chr. 
bp 
Positiona Geneb HR 95% CI p value  HR 95% CI p value  HR 95% CI p value 
rs1878022 12q23.3 108699032 CMKLR1 0.70 (0.54-0.92) 9.8x10-3  0.87 (0.66-1.14) 0.30  0.94 (0.71-1.24) 0.66 
rs1209950 21q22.2 40173528 || ETS2 1.16 (0.90-1.50) 0.24  0.93 (0.70-1.25) 0.65  0.91 (0.68-1.22) 0.53 
rs9981861 21q22.2 41415044 DSCAM 1.08 (0.88-1.33) 0.46  1.13 (0.91-1.39) 0.27  1.15 (0.91-1.45) 0.24 
rs1656402 2q37.1 233426526 EIF4E2 0.93 (0.76-1.14) 0.48  0.90 (0.72-1.11) 0.30  1.11 (0.86-1.43) 0.41 
rs716274c 11q22.3 103418158 DYNC2H1 || 1.02 (0.84-1.23) 0.86  0.97 (0.80-1.17) 0.72  1.21 (0.97-1.50) 0.08 
Models are adjusted for age, sex, treatment, stage, and percent African ancestry. 
adbSNP build 137/GRCH37.p5 
bFor variants outside of gene boundaries, || denotes the location of the variant relative to the closest gene. 
cImputed in KCI/WSU and USCF populations. Imputation score=0.99. 
HR = hazard ratio, CI = confidence interval 
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Table 13. Adjusted multivariable Cox proportional hazards model results for African 
Americans with incident non-small cell lung cancer participating in the Southern 
Community Cohort Study (N=264) for the five candidate SNPs previously associated with 
lung cancer survival from the NHGRI GWAS catalog. 
SNP HR 95% CI p value 
rs1878022 0.68 (0.51-0.89) 5.5x10-3 
rs1209950 1.17 (0.90-1.51) 0.24 
rs9981861 1.10 (0.89-1.36) 0.40 
rs1656402 0.93 (0.76-1.14) 0.50 
rs716274 1.00 (0.82-1.22) 0.99 
Models are adjusted for smoking pack-years, education status, self-reported COPD, age, sex, 
treatment, stage, and percent African ancestry. 
HR = hazard ratio, CI = confidence interval 
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Table 14. Stage-stratified multivariable Cox proportional hazards results for the association of rs1878022 and overall survival 
in the SCCS and pooled KCI/WSU and UCSF populations. 
 SCCS 
(N=275) 
 Pooled KCI/WSU and UCSF 
(N=596) 
Stage N MAF HR 95% CI p value  N MAF HR 95% CI p value 
I 44 0.15 0.65 (0.24-1.74) 0.39  214 0.19 0.99 (0.68-1.46) 0.98 
II/III 87 0.13 1.18 (0.67-2.05) 0.57  218 0.19 0.79 (0.59-1.07) 0.13 
IV 144 0.15 0.62 (0.44-0.88) 7.6x10-3  164 0.16 1.22 (0.86-1.72) 0.27 
Models are adjusted for age, sex, treatment, stage, and percent African ancestry. Pooled KCI/WSU and UCSF models are further 
adjusted for study. 
HR = hazard ratio, CI = confidence interval 
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Table 15. Genotype frequencies for rs1878022 by stage and cohort. 
 TT 
N (%) 
TC 
N (%) 
CC 
N (%) 
Stage I    
   SCCS 31 (70.5) 13 (29.5) 0 (0) 
   WSU 70 (65.4) 32 (29.9) 5 (4.8) 
   UCSF 72 (67.9) 31 (29.2) 3 (2.8) 
Stage II/III    
   SCCS 66 (75.9) 20 (23.0) 1 (1.1) 
   WSU 82 (67.2) 36 (29.5) 4 (3.3) 
   UCSF 61 (64.2) 28 (29.5 6 (6.3) 
Stage IV    
   SCCS 104 (72.2) 38 (26.4) 2 (1.4) 
   WSU 52 (63.4) 29 (35.4) 1 (1.2) 
   UCSF 62 (74.7) 20 (24.1) 1 (1.2) 
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Table 16. Median African ancestry (%, IQR) for each study by stage at diagnosis. 
 SCCS 
% [IQR] 
WSU 
% [IQR] 
UCSF 
% [IQR] 
Stage I 85.9 [76.9, 92.5] 83.1 [73.4, 90.5] 79.7 [70.7, 88.4] 
Stage II/III 85.6 [80.4, 89.3] 83.1 [77.5, 89.8] 84.0 [75.2, 88.8] 
Stage IV 86.4 [80.2, 98.8] 83.6 [72.5, 88.4] 83.3 [74.4, 89.3] 
IQR=interquartile range 
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Table 17. Multivariable Cox proportional hazard results for African Americans with incident non-small cell lung cancer and 
common variants assayed by the Illumina HumanExome BeadChip v1.1. Results are show for associations with a p value 
<1.0x10-4. 
    SCCS (N=275)  KCI/WSU (N=312)  UCSF (N=284) 
SNP Chr 
bp 
Positiona Geneb HR 95% CI p value 
 
HR 95% CI p value 
 
HR 95% CI p value 
rs1133358 20q11.21 31590686 SUN5 0.61 (0.49-0.76) 8.12x10-06  1.01 (0.82-1.24) 0.94  1.08 (0.87-1.35) 0.49 
rs8176785 11p15.1 20805286 NELL1 1.65 (1.32-2.07) 1.20x10-05  0.98 (0.79-1.21) 0.82  1.11 (0.87-1.42) 0.39 
rs7626962 3p22.2 38620907 SCN5A 1.95 (1.44-2.64) 1.44x10-05  1.05 (0.75-1.46) 0.78  0.80 (0.53-1.22) 0.30 
rs605203 6p21.33 31847012 SLC44A4 || EHMT2 0.46 (0.33-0.66) 1.63x10
-05  1.13 (0.82-1.57) 0.43  0.55 (0.38-0.79) 0.001 
rs35761244c 19p13.2 13873698 CCDC130 1.66 (1.32-2.09) 1.68x10-05  0.98 (0.70-1.36) 0.90  0.94 (0.68-1.32) 0.73 
rs6959964 c 7q11.22 68905738 || AUTS2 1.56 (1.27-1.91) 2.21x10-05  0.84 (0.67-1.04) 0.10  0.88 (0.71-1.10) 0.27 
rs1639122 12p13.31 6711147 CHD4 1.80 (1.36-2.38) 3.38x10-05  0.93 (0.74-1.19) 0.58  1.05 (0.78-1.40) 0.76 
rs7138803 12q13.12 50247468 BCDIN3D || FAIM2 1.70 (1.32-2.18) 3.78x10
-05  0.96 (0.74-1.24) 0.74  0.90 (0.69-1.19) 0.48 
rs2072633 6p21.33 31919578 CFB 0.66 (0.54-0.81) 4.07x10-05  1.00 (0.81-1.23) 0.98  0.91 (0.73-1.13) 0.40 
rs1505229 2p12 77589901 LRRTM4 0.67 (0.56-0.82) 5.44x10-05  0.96 (0.78-1.19) 0.72  1.04 (0.84-1.30) 0.72 
rs7502216 17q12 36612948 ARHGAP23 0.67 (0.55-0.81) 5.78x10-05  0.85 (0.69-1.04)) 0.11  1.10 (0.89-1.36) 0.40 
rs537160 6p21.33 31916400 CFB 0.61 (0.48-0.78) 7.44x10-05  0.98 (0.74-1.29) 0.87  0.81 (0.61-1.06) 0.13 
rs7302017 c 12q14.1 63004583 MIRLET7I || PPM1H 1.53 (1.24-1.89) 9.28x10
-05  1.29 (1.01-1.63) 0.04  0.87 (0.67-1.13) 0.30 
Models are adjusted for age, sex, treatment, stage, and percent African ancestry. 
adbSNP build 137/GRCH37.p5 
bFor variants outside of gene boundaries, || denotes the location of the variant relative to the closest gene(s). 
cImputed in KCI/WSU and USCF populations. Imputation score=0.90 for rs35761244, =0.98 for rs6959964, and =0.99 for rs7302017. 
HR = hazard ratio, CI = confidence interval 
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Table 18. Allele frequency for common variants associated with survival in the SCCS 
(N=275), KCI/WSU (N=312), and UCSF (N=284) populations. Allele frequencies are also 
presented for the ASW 1000 Genomes African American reference population. 
SNP Allelea 
SCCS 
MAF 
KCI/WSU 
MAF 
UCSF 
MAF 
ASWb 
MAF 
rs1133358 A/C 0.27 0.26 0.30 0.24 
rs8176785 A/G 0.27 0.31 0.29 0.30 
rs7626962 T/G 0.09 0.10 0.07 0.06 
rs605203 G/T 0.10 0.11 0.11 0.14 
rs35761244 C/G 0.17 0.13 0.14 0.14 
rs6959964 T/C 0.40 0.39 0.42 0.48 
rs1639122 C/A 0.15 0.20 0.18 0.19 
rs7138803 A/G 0.17 0.19 0.19 0.19 
rs2072633 T/C 0.35 0.40 0.42 0.36 
rs1505229 T/C 0.47 0.46 0.49 0.48 
rs7502216 C/A 0.33 0.33 0.35 0.31 
rs537160 T/C 0.17 0.18 0.20 0.22 
rs7302017 G/A 0.27 0.26 0.24 0.30 
 
aEffect/referent allele 
bMinor allele frequency in 1000 Genomes Phase 3 African American samples. 
 
 
Table 19. Functional predictions (PolyPhen-2, SIFT) of amino acid changes for protein 
coding variants with a p value < 1.0x10-4 from the common variant analysis among African 
Americans with incident NSCLC participating in the SCCS (N=275). 
SNP Genea 
Amino Acid 
Change 
PolyPhen-2 
Prediction 
SIFT 
Prediction 
rs1133358 SUN5 E > D Benign Deleterious 
rs8176785 NELL1 R > Q Benign Tolerated 
rs7626962 SCN5A S > Y Benign Deleterious 
rs35761244 CCDC130 C > S Benign Tolerated 
rs1639122 CHD4 E > D Benign Tolerated 
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Table 20. Conditional analysis results for variants on chromosome 6q21.33. Results are 
presented for the Cox proportional hazards model that includes all three variants. 
SNP HR 95% CI p-value 
rs605203 0.56 (0.36-0.87) 1.0x10-2 
rs2072633 0.77 (0.59-1.00) 4.7x10-2 
rs537160 0.98 (0.67-1.42) 0.9 
Model is adjusted for age at diagnosis, sex, African ancestry, stage, and treatment. 
 
 
 
 
Table 21. Adjusted multivariable Cox proportional hazard results for African Americans 
with incident NSCLC in the SCCS (N=264) for common variants assayed by the Illumina 
HumanExome BeadChip v1.1. 
SNP HR 95% CI p valuea 
rs1133358 0.60 (0.48-0.75) 5.8x10-6 
rs8176785 1.69 (1.33-2.14) 1.3 x10-5 
rs7626962 1.96 (1.43-2.68) 3.0x10-5 
rs605203 0.46 (0.32-0.66) 2.5x10-5 
rs35761244 1.74 (1.35-2.24) 1.4x10-5 
rs6959964 1.60 (1.29-1.98) 1.4x10-5 
rs1639122 1.83 (1.38-2.44) 2.7x10-5 
rs7138803 1.68 (1.29-2.19) 1.1x10-4 
rs2072633 0.64 (0.52-0.79) 2.2x10-5 
rs1505229 0.65 (0.53-0.80) 4.1x10-5 
rs7502216 0.66 (0.54-0.81) 5.8x10-5 
rs537160 0.60 (0.47-0.77) 6.6x10-5 
rs7302017 1.56 (1.25-1.95) 9.6x10-5 
 
Models are adjusted for smoking pack-years, education status, self-reported COPD status, age, 
sex, treatment, stage, and percent African ancestry. 
aSorted based on p value presented in Table 3 
HR = hazard ratio, CI = confidence interval!
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Figure 15. Flow chart of quality control (QC) procedures performed on individuals and 
variants in the SCCS and genotyped on the Illumina HumanExome BeadChip. 
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Figure 16. Distribution of stage at diagnosis across the SCCS (N=286), KCI/WSU (N=316), 
and UCSF (N=298). 
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Figure 17. Global genetic ancestry estimates for African Americans with NSCLC 
participating in the (A) SCCS, (B) KCI/WSU, and (C) UCSF study populations. 
African and European ancestry estimated using ADMIXTURE software and ancestry 
informative markers (SCCS) or genome-wide single nucleotide polymorphisms (KCI/WSU and 
UCSF). Supervised analysis (K=2) was performed with the use of YRI and CEU 1000 Genomes 
(phase 3) reference populations. Individuals are sorted from highest African ancestry to least. 
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Figure 18. Meta-analysis of Cox proportional hazard results for rs1878022 in the discovery 
(SCCS, N=275) and replication (KCI/WSU and UCSF, N=312 and 284, respectively) study 
populations. 
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Figure 19. Multivariable Cox proportional hazard results for common SNPs assayed on the 
Illumina HumanExome BeadChip v1.1 and lung cancer survival among African Americans 
with NSCLC in the SCCS (N=275). 
Models are adjusted for age, sex, treatment, stage, and percent African ancestry. 
Solid black line represents our suggestive significance threshold (p value < 1.0x10-4). 
Dashed black line represents a Bonferroni corrected significance threshold (p value < 1.78x10-6) 
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Figure 20. Distribution of the number of SNPs per gene for each test. A, C, E, and G show 
the distribution of SNPs per gene for the SKAT (all variants), SKAT (MAF<5%), burden 
test (all variants), and burden test (MAF <5%), respectively. B, D, F, and G are zoomed in 
to provide a better view of the frequency of genes with 1-50 variants for the SKAT (all 
variants), SKAT (MAF <5%), burden test (all variants), and burden test (MAF <5%), 
respectively. 
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Figure 21. Gene-level association results for all variants using the Sequence Kernel 
Association Test (SKAT). 
 
Figure 22. Gene-level association results for variants with a MAF<5% using the Sequence 
Kernel Association Test (SKAT). 
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Figure 23. Gene-level association results for all variants using the burden test. 
 
Figure 24. Gene-level association results for variants with a MAF<5% using the burden 
test. 
 !  
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Figure 25. Linkage disequilibrium patterns +/-10kb surrounding the CMKLR1 gene region 
in the YRI (A) and CEU (B) 1000 Genomes (phase 3) population. 
LD patterns surrounding rs1878022 (denoted by black arrow) are presented as inserts. 1000 
Genomes data and Haploview software were utilized to display r2 values (filters: Hardy-
Weinberg p-value > 0.001, genotyping efficiency > 90%, and minor allele frequency > 0.05). 
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Figure 26. H3K4me1 and H3K27Ac histone modification marks surrounding rs1878022 in the CMKLR1 gene in (A) normal 
human lung fibroblasts and (B) all cell lines (GM12878, H1-hESC, HSMM, HUVEC, K562, NHEK, and NHLF), visualized 
using UCSC Genome Browser. !
!
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CHAPTER 4 
 
CROSS-CANCER PLEIOTROPIC ANALYSIS OF LUNG CANCER RISK IN AFRICAN 
AMERICANS 
 
Introduction 
Epidemiology of lung cancer risk 
 Lung cancer is a leading cause of cancer worldwide, accounting for an estimated 13% of 
all new cancer cases in 2017 (American Cancer Society 2017). While lung cancer incidence rates 
are second only to breast cancer in women and prostate cancer in men, it is the leading cause of 
cancer-related mortality and is predicted to account for 26% of all cancer-related deaths in the 
United States in 2017 (American Cancer Society 2017). Between 2006 and 2012, the five-year 
survival rate for all races was 19% and 16% for African Americans (American Cancer Society 
2017). Incidence rates also vary by race/ethnicity, with black males accounting for 83.7 new 
cases per 100,000 persons compared to 65.9 and 46.4 new cases per 100,000 persons for white 
and Asian males, respectively (Howlader N). Incidence rates for black, white, and Asian females 
were 49.0, 50.8, and 27.9, respectively (Howlader N). 
 Lung cancer cases can be divided into two main histologic types: small cell and non-
small cell. Small cell lung cancer (SCLC) arises from neuroendocrine cells within the lungs and 
accounts for 13% of all lung cancer cases (Howlader N). The vast majority (84%) of lung cancer 
cases are non-small lung cancer (NSCLC) and can be further divided based on histological 
subtypes, with adenocarcinoma, squamous cell carcinoma, and large cell carcinoma being the 
most prevalent subtypes at 47%, 23%, and 2% of NSCLC cases, respectively (Howlader N).  
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 Lung cancer is most commonly diagnosed in males after 65 years of age (American 
Cancer Society 2017). Additional risk factors include environmental and occupational exposures 
to carcinogens such as radon gas, pollution, gamma-radiation, arsenic, asbestos, and many more 
(Field and Withers 2012). However, smoking remains the highest risk factor for lung cancer and 
accounts for approximately 90% of all lung cancer cases (Prevention 2005), though incidence 
rates have steadily decreased since the mid-1980s for men and 2000s for women in large part due 
to smoking cessation efforts (Howlader N , American Cancer Society 2017).  
 
Genetic studies of lung cancer risk 
 Despite the strong association with tobacco use, 10-15% of lung cancer cases occur in 
nonsmokers (Prevention 2005, Thun et al. 2006, Sisti and Boffetta 2012). In a study of 
nonsmoking lung cancer cases, individuals with a first-degree relative with lung cancer had a 
7.2-fold increased risk for the disease (Schwartz et al. 1996) and heritability estimates range 
from 10-19% (Hemminki et al. 2001, Lorenzo Bermejo and Hemminki 2005, Sampson et al. 
2015). Linkage analysis in 52 pedigrees with multiple affected individuals identified a lung 
cancer susceptibility locus on chromosome 6q23-25 (Bailey-Wilson et al. 2004). The heavily 
replicated lung cancer risk locus is chromosome 15q25.1, which contains nicotinic acetylcholine 
receptor subunit genes CHRNA5, CHRNA3, and CHRNB4 (Amos et al. 2008, Hung et al. 2008, 
Thorgeirsson et al. 2008, Zanetti et al. 2016). Since the discovery of the 15q25.1 risk locus, more 
than 20 additional lung cancer risk loci have been reported through genome-wide association 
studies, though all but one study were conducted in individuals of European- or Asian-descent 
populations (Burdett T (EBI)). 
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Problems with traditional genome-wide association studies 
 Despite the known increased lung cancer incidence in African Americans, very few lung 
cancer genetics studies have been conducted in African-descent individuals, a pattern common 
across genetics research (Popejoy and Fullerton 2016). Furthermore, genome-wide association 
studies are plagued by a high burden of multiple testing and frequently used multiple test 
corrections can be too stringent, often resulting in true associations being rejected as false 
positives. While study sample sizes are increasing in large part due to decreased genotyping 
costs, power to detect such associations remains limited. One method of identifying previously 
undetected associations is by reducing the number of SNPs being examined to those with a 
priori biological evidence. 
 
Pleiotropy 
 Pleiotropy occurs when a genetic locus is associated with more than one trait (Solovieff 
et al. 2013). Pleiotropy has been observed across multiple phenotypes, including cancer (Cheng 
et al. 2014, Panagiotou et al. 2014, Park et al. 2014, Fehringer et al. 2016). For example, 
mutations in the telomerase reverse transcriptase (TERT) gene have been associated with 
telomere length (Liu et al. 2014), pulmonary fibrosis (Fingerlin et al. 2013), red blood cell count 
(Kamatani et al. 2010), breast cancer (Couch et al. 2016), lung cancer (McKay et al. 2008, Landi 
et al. 2009, Hsiung et al. 2010), glioma (Kinnersley et al. 2015), pancreatic cancer (Wolpin et al. 
2014), and prostate cancer (Berndt et al. 2015), to name a few (Mocellin et al. 2012). Cross-
cancer pleiotropic effects in lung cancer have previously been examined in a European descent 
population and identified a significant association with a single variant in LSP1 gene, which had 
been previously associated with breast cancer risk (Park et al. 2014). A 2016 study by Fehringer 
! 102 
et al. identified additional cross-cancer pleiotropic associations for lung cancer with 
ADAM15/THBS3, CDKN2B-AS1, and BRCA2 genes. It remains necessary, however, to examine 
these associations in African American individuals. 
 
Rationale 
 The present study sought to identify novel pleiotropic associations for lung cancer risk in 
African Americans by examining variants previously associated with cancer risk and reported in 
the National Human Genome Research Institute (NHGRI) - European Bioinformatics Institute 
(EBI) Genome-Wide Association Study (GWAS) Catalog. By selecting variants with a priori 
evidence for an association with cancer, we are able to reduce the high burden of multiple testing 
incurred by traditional genome-wide association studies, thereby increasing the possibility of 
detecting novel lung cancer risk associations. Unlike previous studies of pleiotropy across cancer 
types, the present analysis also accounts for differing patterns of linkage disequilibrium between 
racial/ethnic populations, further expanding our ability to detect cross-cancer and cross-
population associations. 
 
Methods 
Study population 
 African American lung cancer cases and controls were selected from six studies 
participating in the African American Lung Cancer Consortium: MD Anderson (MDA) Lung 
Cancer Epidemiology Study, Project CHURCH (Creating a Higher Understanding of Cancer 
Research & Community Health, an MD Anderson Cancer Center study), NCI-MD Lung Cancer 
Case Control Study, Northern California Lung Cancer Study from the University of California, 
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San Francisco (UCSF), the Southern Community Cohort Study (SCCS), and the Karmanos 
Cancer Institute at Wayne State University (KCI/WSU) (Zanetti et al. 2016). A detailed 
description of each study has been previously reported (Zanetti et al. 2016). All studies were 
approved by the Institutional Review Board at each respective institution and written informed 
consent was obtained for all participants.   
 
Genotyping, quality control, and imputation 
 All samples were genotyped on the Illumina Human Hap 1M Duo array at the NCI 
Cancer Genomics Research Laboratory (CGR) in the Division of Cancer Epidemiology and 
Genetics (DCEG) at the National Cancer Institute. A detailed description of the quality control 
(QC) process is provided (Figure 27). Briefly, SNPs were excluded if they were non-autosomal, 
had a MAF <1%, <95% genotyping efficiency, or a Hardy-Weinberg Equilibrium (HWE) p-
value <0.000001. Individuals were excluded if they had a <95% genotyping efficiency. Pairwise 
identity-by-descent was also examined to identify related individuals; for each genetically related 
pair, the individual with the lowest genotyping efficiency was excluded (N=146). No individuals 
were excluded due to inconsistencies between reported and genetic sex, but four individuals with 
an “unknown” reported sex were filled in based on the calculated genetic sex. All quality control 
filtering was applied using PLINK (Purcell et al. 2007). 
Missing genotypes were imputed using IMPUTE2 (Howie et al. 2009), with pre-phasing 
performed using SHAPEIT (Delaneau et al. 2008, Delaneau et al. 2011, Delaneau et al. 2013).  
Haplotypes from the cosmopolitan 1000 Genomes phase 3 population consisting of 2,504 
individuals from 27 countries were used as a reference population. SNPs imputed with low 
certainty were excluded based on an info score <0.4, MAF<0.01, and HWE p-value <0.00001. 
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Ancestry estimation 
  Supervised admixture analysis was performed using ADMIXTURE software (Alexander 
et al. 2009) to obtain global estimates of African and European ancestry for all individuals. 
Admixture analysis was performed on pre-imputation genotypes merged with the CEU (CEPH 
Utah residents with Northern and Western European ancestry) and YRI (Yoruba from Ibadan, 
Nigeria) HapMap reference populations (International HapMap Consortium 2003), and pruned to 
a set of unlinked variants (window size = 50, step size = 10, r2 > 0.1). A total of 140,591 variants 
remained for supervised (k=2) admixture analysis.  
 
Selection of variants for pleiotropic analysis 
 Cancer-associated variants were identified from the NHGRI-EBI GWAS catalog. The 
catalog was queried based on the search term “neoplasm” on April 27, 2016. Manual review 
excluded studies in which the outcome was not risk (i.e. outcomes such as survival, prognosis, 
toxicity, relapse, or another disease). Interaction studies were also excluded. SNPs from each of 
the remaining studies were aggregated into a single list, hereafter referred to as “reported SNPs.”  
 We further expanded our list of SNPs based on linkage disequilibrium patterns of the 
1000 Genomes (phase 3) reference population (Genomes Project et al. 2015, Sudmant et al. 
2015) matching the race/ethnicity of the population used in the reported GWAS Catalog study. 
For example, the CHB (Han Chinese in Beijing, China) reference population was used to identify 
SNPs in LD with variants reported in an Asian-descent population, while the CEU (CEPH Utah 
Residents with Northern and Western European Ancestry) reference population was used for 
SNPs reported in European-descent populations. For the admixed Latino/a and African American 
populations we used all relevant reference populations: CEU, CHB, YRI (Yoruba in Ibadan, 
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Nigeria), and MXL (Mexican Ancestry from Los Angeles) for Latino/a and CEU, YRI, and 
ASW (Americans of African Ancestry in SW United States) for African American. We tested 
four different methods for selecting variants based on LD on five randomly selected SNPs 
previously identified in a European population: 1) the PLINK tag-SNP selection function with 
default r2 and window settings (--show-tags, default settings of r2>0.8, +/-250kb), 2) the PLINK 
tag-SNP selection with specified r2 and window range (r2>0.6, +/-100kb), 3) the PLINK pairwise 
LD estimation (--ld-snp, r2>0.6, +/-100kb), and 4) the online NIH/NIEHS LD Tag SNP selection 
tool (https://snpinfo.niehs.nih.gov/snpinfo/snptag.php). These results were compared to a SNP-
selection method that included all SNPs +/-100kb of the reported SNP. A final list of SNPs for 
analysis was generated using the PLINK pairwise LD estimation method (r2>0.6, +/-100kb), 
hereafter referred to as the “selected SNPs.” Selected SNPs were extracted from the imputed 
genotyping data based on chromosome and position. 
 
Statistical analysis 
 Logistic regression was performed for each additively coded variant using SNPTest to 
account for imputation probabilities (Marchini et al. 2007). Age, sex, smoking status 
(current/former/never), global African ancestry, and study site were included as covariates in the 
logistic regression models. A Benjamini- Hochberg false discovery rate (FDR) correction was 
applied to p-values to account for multiple testing. Each study site was then individually 
examined using SNPTest (adjusted for age, sex, smoking status, and global African ancestry) and 
meta-analyzed using METAL. Samples were additionally stratified by histology, smoking status, 
and sex to evaluate strata-specific associations. A formal test of interaction was then performed 
for SNPs with FDR-corrected p-values ≤ 0.10 in either sex- or smoking status-stratified analysis. 
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Results 
Descriptive Characteristics A!total!of!4,253!African!American!individuals!remained!following!quality!control,!including!1,410!cases!and!2,843!controls.!Forty@five!percent!of!all!samples!were!male!and!the!mean!age!at!diagnosis!was!58!years!(standard!deviation!=!12.5).!Never!smokers!accounted!for!36%!of!all!individuals,!with!current!and!former!smokers!accounting!for!31%!and!32%!of!individuals,!respectively.!The!median!global!African!ancestry!was!83%.!Among!cases,!45%!of!individuals!had!adenocarcinoma,!followed!by!24%!of!individuals!with!squamous!cell!carcinoma.!Small!cell!carcinoma!represented!6%!of!cases.!Descriptive!characteristics!by!study!and!case/control!status!are!presented!in!Table 22.!!
 
Variant Selection ! A!total!of!266!unique!studies!were!extracted!from!the!NHGRI@EBI!GWAS!Catalog!based!on!the!search!term!“neoplasm.”!Forty@six!studies!were!excluded!after!manual!review,!resulting!in!220!studies!reporting!risk!associations!for!959!unique!SNPs!(“reported!SNPs”).!Seventy@four!percent!(163!out!of!220)!of!studies!were!conducted!in!European@descent!populations,!followed!by!26%!(57!of!220)!in!Asian@descent!populations2 (Table 23).!The!admixed!Latino/a!and!African!American!populations!accounted!for!only!3%!and!5%!of!included!studies2 (Table 23).!Of!all!reported!SNPs,!629!were!directly!observed!in!the!genotype!data!and!an!additional!294!were!imputed.!Thirty@six!reported!SNPs!were!not!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
2 The sum of percentages is greater than 100 because 11 studies used multiple racial/ethnic populations.!
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present!in!the!1000!Genomes!reference!populations!used!for!LD@based!selection!of!SNPs!and!were!dropped!from!analysis.!!
Because!genotyping!arrays!are!designed!to!capture!genome@wide!variation!using!as!few!SNPs!as!possible,!the!majority!of!reported!associations!are!rarely!causal,!but!rather!correlated!(or!in!linkage!disequilibrium)!with!the!true!causal!variant.!Additionally,!we!know!that!linkage!disequilibrium!(LD)!patterns!differ!between!racial/ethnic!groups.!Since!the!vast!majority!of!the!reported!SNPs!are!identified!in!European@!or!Asian@descent!populations,!we!selected!variants!in!LD!with!the!reported!SNP!in!the!1000!Genomes!reference!population!matching!the!race/ethnicity!of!the!population!reported!in!the!NHGRI@EBI!GWAS!Catalog.!We!evaluated!five!methods!for!extracting!variants!based!on!LD!for!five!randomly!selected!SNPs!previously!identified!in!a!European@descent!population!using!the!CEU!reference!population!(Table 24).!Only!one!method,!NIH/NIEHS!LD!Tag!SNP!Selection,!failed!to!identify!any!additional!SNPs!to!examine.!Both!PLINK!tag!SNP!selection!methods!(default!and!user@specified!settings)!and!the!PLINK!pairwise!LD!estimation!method!produced!similar,!though!non@identical!results!(Table 24).!For!all!PLINK!LD@based!methods!tested,!the!number!of!additional!SNPs!identified!ranged!from!0!to!45!for!the!five!tested!SNPs.!This!was!substantially!less!than!the!784@979!SNPs!identified!when!LD!was!not!considered!(Table 24).!Given!the!discrepancy!between!the!PLINK!tag!SNP!selection!and!PLINK!pairwise!LD!estimation!methods!even!when!the!same!parameters!(r2>0.6,!+/@100kb)!were!set,!we!chose!to!apply!the!later!method!to!all!reported!variants,!in!large!part!because!we!were!most!familiar!with!the!underlying!methodology.!Additionally,!the!PLINK!pairwise!LD!estimation!method!allowed!us!to!still!perform!hypothesis@based!testing,!whereas!selecting!all!variants!within!the!+/@100kb!region!regardless!of!LD!would!
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undoubtedly!result!in!testing!SNPs!that!have!zero!correlation!with!the!reported!SNP,!thereby!negating!our!hypothesis!driven!approach.!Application!of!the!PLINK!pairwise!LD!estimation!method!to!all!reported!SNPs!increased!our!number!of!SNPS!to!be!examined!to!39,010!(Table 23).!For!the!20!and!49!SNPs!originally!identified!in!admixed!Latino!or!African!American!populations,!we!applied!the!PLINK!pairwise!LD!estimation!method!to!all!relevant!reference!populations!(Table 23)!and!examined!the!overlap!between!selected!SNPs!in!all!populations!(Figure 28!and!Figure 29).!
 
Logistic Regression Analysis 
 Approximately 1,700 selected SNPs were neither observed nor imputed in our African 
American population and 280 SNPs failed to meet post-imputation quality control filtering, 
resulting in 36,958 selected SNPs for analysis. Logistic regression analysis revealed 28 SNPs 
with an FDR-corrected p-value less than 0.05 and an additional 12 with a p-value less than 0.10 
(Figure 30). The most statistically significant peak of association was chromosome 15q25 (odds 
ratio (OR)=1.41, 95% confidence interval (CI): 1.26-1.57), followed by chromosome 5p15 
(OR=0.79, 95% CI: 0.71-0.88, Table 25). Three additional SNPs on chromosomes 5q14.3, 
16q22.2, and 17q12 also had significant associations with lung cancer risk. The C allele at 
rs336958 on 5q14.3 was associated with reduced risk with an OR of 0.68 and 95% CI of 0.56-
0.82.  The peak on chromosome 16q22.2 consisted of four SNPs with similar effect sizes, though 
only one, rs7186207, surpassed a 10% FDR correction threshold (OR=1.24, 95% CI=1.12-1.38, 
FDR p-value = 0.04). Similarly, the G allele at rs11658063 on chromosome 17q12 had an OR of 
1.24 and 95% CI of 1.11-1.39. One additional SNP in the 17q12 region had a similar effect size, 
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but did not surpass the 10% FDR threshold. Similar results were observed when study sites were 
meta-analyzed (Figure 32).  
  
Stratified Analyses 
 To identify subtype-specific associations for lung cancer risk, we examined 
adenocarcinoma cases and squamous cell carcinoma cases separately. No genetic variant was 
significantly associated with lung cancer risk in either histological subtype (Figure 32 and Figure 
33). The smallest FDR-corrected p-value was 0.18 in adenocarcinoma cases for a SNP on 
chromosome15q25 (Table 26). Among squamous cell carcinoma cases, the most significant SNP 
was rs1950005 on chromosome 6q25.2, though the FDR-corrected p-value was 0.48 (Table 27).  
 Stratification by sex and smoking status revealed the chromosome 15q25 association was 
among females only and ever smokers only (Figure 34 and Figure 36). Beyond the peak on 
15q25, no other SNP passed a 10% FDR correction threshold among women only, though the 
risk (G) allele at rs7486184 on chromosome 12q21.32 was associated with an OR of 1.35 (95% 
CI=1.17-1.55) at an FDR-corrected p-value of 0.10, just above our statistical significance 
threshold (Figure 34 and Table 28). No SNPs were significant after an FDR correction in males 
(Table 29). Among ever smoking individuals, the association at chromosome 15q25 was by far 
the most significant signal. However, two other peaks also surpassed a 10% FDR threshold: 
chromosome 5p15.33 and 16q22.2 (Figure 36 and Table 30). While no p-values were statistically 
significant after FDR correction in never smokers, peaks at chromosome 5p15.33 and 15q25 had 
p-values of suggestive significance (FDR-corrected p-value = 0.13, Figure 37 and Table 31).  
 The 33 SNPs among ever smokers and 12 SNPs among females with an FDR-corrected 
p-value ≤ 0.10 were then examined for an interaction with smoking and sex, respectively. No 
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significant SNP*smoking interactions were present among the 33 SNPs associated with lung 
cancer risk among ever smokers (Table 32). Of the 12 SNPs associated with lung cancer risk 
among females, 9 showed significant evidence of a SNP*sex interaction (Table 33).  
 
Discussion 
 The present analysis sought to identify cross-cancer pleiotropic genetic associations for 
lung cancer risk in African Americans. The two most statistically significant peaks were on 
chromosome 15q25 and 5p15, both of which have been previously associated with lung cancer in 
African Americans (Schwartz et al. 2009, Walsh et al. 2012, Walsh et al. 2013) and recently 
validated in a large African American population that included all cases and controls utilized in 
the present study (Zanetti et al. 2016). Stratification by sex and smoking status revealed strong 
signals of association among women and ever smokers, suggesting the observed association 
among all individuals may be driven by these two subgroups. However, it should not go 
unnoticed that, despite not meeting our threshold for statistical significance, there was evidence 
for an association of 5p15 and 15q25 among never smokers (FDR-corrected p-values = 0.13, 
Table 31). Furthermore, this confirms previous research noting the direct association between 
gene region 15q25 and lung cancer risk in addition to its association mediated by nicotine 
dependence (Hung et al. 2008, Thorgeirsson et al. 2008).   
In addition to the previously described associations on 5p15 and 15q25, our study also 
identified three additional significant associations on chromosomes 5q14.3, 16q22.2, and 17q12 
among all individuals. Chromosome 16q22.2 was also observed among ever smokers and an 
additional peak on 12q21.32 was observed among women. Excluding 5p15 and 15q25, the most 
significant association was for rs7186207 on chromosome 16q22.2 (FDR-corrected p-value = 
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0.04). All four SNPs in this region (rs7186207, rs8051239, rs7195958, and rs3213422) had risk 
alleles with odds ratios of approximately 1.24 and 95% confidence intervals from 1.12 to 1.38 
and were in strong LD (r2 > 0.68.) with each other in both African (YRI and ASW) and European 
(CEU) 1000 Genomes Reference Populations. Given the high degree of correlation between 
variants, it is unsurprising that risk allele frequencies were similar, ranging from 0.56 to 0.62. 
None of the four SNPs were among the reported SNPs extracted from the GWAS Catalog, but 
were selected because of their strong linkage disequilibrium (r2 = 0.75-0.78) with rs12597458, a 
variant previously associated with prostate cancer risk (Berndt et al. 2015). Additional SNPs in 
the 16q22.2 region have also been associated with prostate cancer (Al Olama et al. 2014), though 
none of those SNPs were identified here. SNPs rs7186207, rs8051239, and rs7195958 are 
intergenic and located between PKD1L3 and DHODH and do not appear to be located at sites 
with regulatory potential (Figure 38). The remaining SNP at this locus, rs3213422, is located 
within the first intron of DHODH and encodes a missense mutation, though SIFT and PolyPhen 
both predict the mutation to be tolerated/benign (Figure 38). Given its close proximity to the 
exon boundary, variation at rs3213422 could also affect exon splicing. ENCODE data reveal 
H3K4me3 and H3K27ac markers surrounding rs3213422, indicative of active promoters and 
regulatory elements, as well as evidence for transcription factor binding (Figure 38). Given the 
lack of regulatory evidence for rs7186207, rs8051239, and rs7195958, it is possible that their 
association with lung cancer risk in the present study is due to their high correlation with 
rs3213422, which has clear regulatory potential.  
 The DHODH, or dihydroorotate dehydrogenase, gene encodes a 43-kDa enzymatic 
protein localized to the inner mitochondrial membrane, where it interacts with the mitochondrial 
respiratory chain (Evans and Guy 2004, Khutornenko et al. 2010, Fang et al. 2013). Mutations 
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within DHODH have been linked with Miller Syndrome, a recessive disorder characterized by 
malformations of the limbs and eyes, among other symptoms (Ng et al. 2010, Kinoshita et al. 
2011, Fang et al. 2012, Rainger et al. 2012). DHODH is also being investigated for a role in 
cancer (White et al. 2011). Most recently, decreased expression of DHODH was associated with 
breast cancer risk (Hoffman et al. 2017). Several other studies have examined the utility of 
DHODH inhibitors in inducing apoptosis in cancer cells (Baumann et al. 2009, Zhu et al. 2013, 
He et al. 2014). While DHODH has not been previously associated with lung cancer risk, the 
abundance of biological evidence for its role in cancer gives credibility to the association and 
stresses the importance of performing a replication analysis in an independent population of 
African American lung cancer cases and controls and fine mapping the region to better 
understand the underlying mechanism. 
 Analysis of all individuals identified significant associations on chromosomes 5q14.3 and 
17q12. Chromosome 5q14.3 SNP rs336958 is an intronic variant for HAPLN1, hyaluronan and 
proteoglycan link protein 1, which has been shown to play a role in cell adhesion and 
extracellular matrix structure. rs336958 is in LD (r2=0.97) with rs4466137, which is reported in 
the GWAS catalog for an association with prostate cancer risk (Murabito et al. 2007). The larger 
5q14.3 region has also been associated with prostate cancer, breast cancer and Wilms tumors 
(Turnbull et al. 2012, Cai et al. 2014, Berndt et al. 2015). The most significant SNP on 
chromosome 17q12 is rs11658063, a variant located in the first intron of HNF1B. HNF1 
homeobox B (HNF1B) encodes a transcription factor and has been shown to play a role in cell 
development. Studies have also linked HNF1B to hepatocellular cancer prognosis and have 
investigated its utility as a biomarker in breast cancer (Yu et al. 2015, Huang et al. 2016, 
Bubancova et al. 2017). The final notable peak of association was on chromosome 12q21.32, in 
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which rs7486184 was associated with lung cancer in females. The intergenic variant rs7486184 
is located approximately 50 kb downstream of the previously reported variant rs995030, which 
has been previously associated with testicular cancers (Rapley et al. 2009, Chung et al. 2013, 
Ruark et al. 2013).   
 While previous studies have examined pleiotropy in lung cancer (Park et al. 2014, 
Fehringer et al. 2016), few have considered differences in LD structure between racial/ethnic 
groups. Such considerations are especially important given recent publications noting the non-
transferability of genetic risk predictions across diverse populations (Manrai et al. 2016, Martin 
et al. 2017). In the present analysis, we expanded the list of reported SNPs by considering the LD 
structure of the racial/ethnic population each SNP was discovered in, thus removing the 
assumption that the reported SNP has the same correlation structure, and therefore, tagging 
ability, with the causal SNP in all racial/ethnic groups. Of the six methods for expanding our list 
of reported SNPs examined here, only one (NIH/NIEHS LD Tag SNP Selection) identified no 
additional SNPs. This is likely due to the fact that the selection method uses genotyping data 
from HapMap reference populations, which provide sparser information compared to whole 
genome sequencing data from the 1000 Genomes reference populations that utilized in our other 
approaches. Importantly, it was only through consideration of LD structure that the present study 
was able to identify novel lung cancer risk associations, as none of the most significant SNPs 
were among the list of reported SNPs extracted from the GWAS catalog.  
The first African American genome-wide association study was published by Zanetti et 
al. in 2016 and was also the largest study of lung cancer in African Americans. It is of utmost 
importance to note that the present study is not independent from the former as our cases and 
controls were a subset of the individuals utilized by Zanetti et al. However, our study restricted 
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analysis to SNPs with a priori evidence to examine cross-cancer pleiotropic associations. Our 
study was able to identify novel lung cancer risk loci that may have been missed due to stringent 
multiple test corrections required in genome-wide association studies. 
Given our large sample size, we are adequately powered to detect the associations 
reported here (Figure 39). While our primary analysis lacked a replication population, meta-
analysis of all five studies revealed results consistent to the pooled analysis, confirming our 
results. Despite the internal replication, future analyses should confirm these associations in an 
independent population of African American lung cancer cases and controls. Future analyses 
should confirm these associations in other racial/ethnic groups and focus on fine mapping of the 
chromosome 16q22.2 region to better understand its impact on lung cancer risk.  
 
 
! 115 
Table 22. Descriptive characteristics of African American lung cancer cases and controls. 
Characteristic 
 
MDA 
N=1374 
 
NCI 
N=583 
 
SCCS 
N=506 
 
UCSF 
N=986 
 
WSU 
N=804  
Total 
 
    
Cases 
N=1,410 
Controls 
N=2,843 
Combined 
N=4,253 
Status               
  Cases, N (%)  373 (27.1)  208 (35.7)  168 (33.2)  325 (33.0)  336 (41.8)    1,410 (33.2) 
  Controls, N (%)  1001 (72.9)  375 (64.3)  338 (66.8)  661 (67.0)  468 (58.2)    2,843 (66.8) 
Sex               
  Male  525 (38.2)  308 (52.8)  300 (59.3)  450 (45.6)  317 (39.4)  698 (49.5) 1,202 (42.3) 1,900 (44.7) 
  Female  849 (61.8)  275 (47.2)  206 (40.7)  536 (54.4)  487 (60.6)  712 (50.5) 1,641 (57.7) 2,353 (55.3) 
Mean age at diagnosis, yr (SD)  52.2 (13.5)  64.4 (9.6)  55.9 (8.9)  63.5 (11.2)  60.3 (11.3)  61.5 (10.5) 56.9 (13.2) 58.4 (12.6) 
Smoking Status               
  Current, N (%)  339 (24.8)  196 (33.7)  276 (54.8)  364 (38.1)  358 (44.6)  778 (55.3) 755 (27.0) 1,533 (36.4) 
  Former, N (%)  379 (27.7)  250 (43.0)  111 (22.0)  361 (37.8)  257 (32.0)  520 (36.9) 838 (29.9) 1,358 (32.3) 
  Never, N (%)  649 (47.5)  135 (23.2)  117 (23.2)  230 (24.1)  187 (23.3)  110 (7.8) 1,208 (43.1) 1,318 (31.3) 
Median African Ancestry, %   82.6  82.4  88.3  81.9  82.9  83.6 83.1 83.2 
Histology               
  Adenocarcinoma, N (%)  173 (46.4)  97 (47.1)  47 (31.3)  145 (44.6)  170 (50.6)  632 (45.5) - 632 (45.5) 
  Squamous Cell, N (%)  103 (27.6)  53 (25.7)  28 (18.7)  82 (25.2)  71 (21.1)  337 (24.2) - 337 (24.2) 
  Large Cell, N (%)  2 (0.5)  5 (2.4)  11 (7.3)  4 (1.2)  12 (3.6)  34 (2.4) - 34 (2.4) 
  Small Cell, N (%)  23 (6.2)  2 (1.0)  14 (9.3)  20 (6.0)  22 (6.8)  81 (5.8) - 81 (5.8) 
  Other, N (%)  72 (19.3)  49 (23.8)  50 (33.3)  72 (22.2)  63 (18.8)  306 (22.0) - 306 (22.0) !
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Table 23. Number of studies and variants reported in the NHGRI-EBI GWAS Catalog and 
the number of SNPs identified after selecting based on LD. 
Race/Ethnicity in 
GWAS Catalog 
Number of 
Studies 
Number of 
SNPs 
1000 Genomes 
Population Used 
for LD Selection 
Number of 
SNPs after 
LD Selection 
European 163 743 CEU 29,727 
Asian 57 217 CHB 10,625 
Latino 6 20 CEU, YRI, MXL, CHB 968 
African American 11 49 CEU, YRI, ASW 1,490 
Total  220 959  39,010 
 
 
Table 24. Number of additional SNPs extracted by each method for five randomly selected 
SNPs previously identified in European-descent populations. 
Reported 
SNP 
All SNPs 
(r2>0, +/-
100kb) 
PLINK 
pairwise LD 
estimation 
(r2>0.6, +/-
100kb) 
PLINK tag 
SNP 
selection 
(default 
settings) 
PLINK tag 
SNP 
selection 
(r2>0.6, +/-
100kb) 
NIH/NIEHS 
LD Tag SNP 
Selection 
rs12413624 960 18 10 16 0 
rs6772209 949 1 0 0 NA 
rs34479159 869 12 9 10 NA 
rs7632500 979 45 36 43 0 
rs7580717 784 34 15 32 0 
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Table 25. SNPs significantly associated with lung cancer risk among African American 
lung cancer cases and controls (N=4,253). 
SNP Chr. BP 
Risk/ 
Ref. 
Allele 
Risk 
Allele 
Freq 
Info 
Score OR 95% CI 
Unadjusted 
P-value 
FDR 
P-value 
rs17486278 15 78867482 C/A 0.3 1 1.41 (1.26-1.57) 6.27E-10 2.32x10-5 
rs55781567 15 78857986 G/C 0.28 1 1.37 (1.23-1.53) 1.54E-08 2.84x10-4 
rs2036527 15 78851615 A/G 0.23 1 1.36 (1.21-1.54) 2.87E-07 2.89x10-4 
rs58365910 15 78849034 C/T 0.27 0.98 1.35 (1.2-1.51) 3.13E-07 2.89x10-4 
rs147144681 15 78900908 T/C 0.18 1 1.36 (1.2-1.55) 2.14E-06 0.01 
rs576982 15 78870803 T/C 0.29 1 0.77 (0.69-0.86) 2.74E-06 0.01 
rs664172 15 78862762 A/G 0.28 1 0.76 (0.68-0.85) 2.17E-06 0.01 
rs667282 15 78863472 C/T 0.29 1 0.76 (0.68-0.85) 1.91E-06 0.01 
rs938682 15 78896547 A/G 0.72 1 1.3 (1.17-1.46) 2.56E-06 0.01 
rs569207 15 78873119 T/C 0.28 1 0.77 (0.69-0.86) 3.71E-06 0.01 
rs637137 15 78873976 A/T 0.29 1 0.77 (0.69-0.86) 4.15E-06 0.01 
rs11637630 15 78899719 A/G 0.71 0.99 1.29 (1.16-1.44) 5.35E-06 0.01 
rs2456020 15 78868398 T/C 0.4 1 0.79 (0.71-0.87) 5.52E-06 0.01 
rs55676755 15 78898932 G/C 0.17 1 1.35 (1.19-1.54) 5.69E-06 0.01 
rs7183604 15 78899213 C/T 0.72 0.99 1.3 (1.16-1.45) 4.87E-06 0.01 
rs12440014 15 78926726 G/C 0.22 0.91 0.75 (0.66-0.85) 6.39E-06 0.01 
rs3825845 15 78910258 T/C 0.23 1 0.76 (0.68-0.86) 8.24E-06 0.02 
rs503464 15 78857896 A/T 0.27 0.98 0.77 (0.69-0.87) 1.00E-05 0.02 
rs189218934 15 78903987 C/T 0.73 0.99 1.29 (1.15-1.44) 1.08E-05 0.02 
rs113931022 15 78901113 T/C 0.19 1 1.32 (1.16-1.5) 2.18E-05 0.04 
rs138544659 15 78900701 G/T 0.19 1 1.32 (1.16-1.49) 2.21E-05 0.04 
rs112878080 15 78900647 G/A 0.19 1 1.32 (1.16-1.49) 2.21E-05 0.04 
rs2853677 5 1287194 A/G 0.71 1 0.79 (0.71-0.88) 2.28E-05 0.04 
rs111704647 15 78900650 T/C 0.19 1 1.31 (1.16-1.49) 2.50E-05 0.04 
rs2735940 5 1296486 G/A 0.47 0.98 0.81 (0.73-0.89) 2.60E-05 0.04 
rs7186207 16 72035359 C/T 0.57 1 1.24 (1.12-1.38) 2.66E-05 0.04 
rs2853672 5 1292983 A/C 0.47 1 0.81 (0.73-0.89) 2.85E-05 0.04 
rs56077333 15 78899003 A/C 0.19 1 1.31 (1.15-1.49) 3.24E-05 0.04 
rs7170068 15 78912943 A/G 0.23 0.99 0.78 (0.69-0.88) 3.93E-05 0.05 
rs1051730 15 78894339 A/G 0.12 1 1.37 (1.18-1.6) 5.00E-05 0.06 
rs28491218 15 78267947 C/T 0.22 0.91 0.77 (0.68-0.87) 5.43E-05 0.06 
rs951266 15 78878541 A/G 0.11 0.99 1.39 (1.18-1.63) 5.28E-05 0.06 
rs12914385 15 78898723 T/C 0.2 1 1.29 (1.14-1.46) 5.69E-05 0.06 
rs336958 5 82973396 C/T 0.92 1 0.68 (0.56-0.82) 5.90E-05 0.06 
rs7172118 15 78862453 A/C 0.11 0.99 1.38 (1.18-1.62) 6.73E-05 0.07 
rs28360704 15 78268603 T/C 0.21 0.94 0.77 (0.68-0.88) 8.70E-05 0.08 
rs56390833 15 78877381 A/C 0.11 1 1.38 (1.17-1.62) 8.10E-05 0.08 
rs7180002 15 78873993 T/A 0.11 1 1.38 (1.17-1.61) 8.42E-05 0.08 
rs905739 15 78845110 G/A 0.25 0.98 0.79 (0.7-0.89) 8.77E-05 0.08 
rs11658063 17 36103872 G/C 0.61 0.88 1.24 (1.11-1.39) 1.04E-04 0.10 
rs16969968 15 78882925 A/G 0.07 1 1.49 (1.22-1.83) 1.14E-04 0.10 
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Table 25 continued. SNPs significantly associated with lung cancer risk among African American lung cancer 
cases and controls 
SNP Chr. BP 
Risk/ 
Ref. 
Allele 
Risk 
Allele 
Freq 
Info 
Score OR 95% CI 
Unadjusted 
P-value 
FDR 
P-value 
rs8192482 15 78886198 T/C 0.07 1 1.49 (1.22-1.83) 1.18E-04 0.10 
rs8051239 16 72036257 A/T 0.62 1 1.23 (1.1-1.36) 1.31E-04 0.11 
rs11633958 15 78862064 T/C 0.07 0.99 1.47 (1.2-1.79) 1.57E-04 0.13 
rs140330585 15 78866445 A/G 0.13 0.99 1.34 (1.15-1.56) 1.64E-04 0.13 
rs17486195 15 78865197 G/A 0.13 0.99 1.34 (1.15-1.56) 1.73E-04 0.13 
rs3734131 5 95278679 A/G 0.4 1 0.82 (0.75-0.91) 1.72E-04 0.13 
rs3777175 5 95277555 G/A 0.4 1 0.82 (0.75-0.91) 1.68E-04 0.13 
rs4243084 15 78911672 C/G 0.2 0.99 1.27 (1.12-1.45) 1.60E-04 0.13 
rs7195958 16 72036577 G/A 0.62 1 1.22 (1.1-1.36) 1.53E-04 0.13 
rs72740964 15 78868636 A/G 0.07 1 1.48 (1.21-1.81) 1.68E-04 0.13 
rs28534575 15 78923845 G/T 0.25 0.93 0.8 (0.71-0.9) 1.93E-04 0.14 
rs146009840 15 78906177 T/A 0.07 0.99 1.47 (1.2-1.79) 2.05E-04 0.14 
rs518425 15 78883813 G/A 0.49 1 0.83 (0.75-0.92) 2.00E-04 0.14 
rs55853698 15 78857939 G/T 0.09 0.99 1.41 (1.17-1.68) 2.01E-04 0.14 
rs4887072 15 78925435 G/A 0.25 0.93 0.8 (0.71-0.9) 2.10E-04 0.14 
rs11263763 17 36103565 A/G 0.61 0.89 1.23 (1.1-1.37) 2.29E-04 0.15 
rs3213422 16 72042682 C/A 0.56 1 1.17 (1.06-1.3) 1.91E-03 0.51 
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Table 26. Top SNPs associated with lung cancer risk among African American lung 
adenocarcinoma cases and controls (N=3,475). 
SNP Chr. BP 
Risk/ 
Ref. 
Allele 
Risk 
Allele 
Freq. 
Info 
Score OR 95% CI 
Unadjusted 
P-value 
FDR 
P-value 
rs17486278 15 78867482 C/A 0.29 1 1.39 (1.21-1.6) 4.75E-06 0.18 
rs55781567 15 78857986 G/C 0.27 1 1.31 (1.14-1.51) 2.19E-04 0.46 
rs10509798 10 107503741 T/C 0.26 1 0.78 (0.67-0.9) 8.19E-04 0.46 
rs111493981 10 107501561 T/C 0.26 1 0.78 (0.67-0.9) 8.17E-04 0.46 
rs111964481 10 107495801 G/A 0.26 1 0.78 (0.67-0.9) 7.50E-04 0.46 
 
Table 27. Top SNPs associated with lung cancer risk among African American lung 
squamous cell carcinoma cases and controls (N=3,180). 
SNP Chr. BP 
Risk/ 
Ref. 
Allele 
Risk 
Allele 
Freq. 
Info 
Score OR 95% CI 
Unadjusted  
P-value 
FDR 
P-value 
rs55781567 15 78857986 G/C 0.26 1 1.5 (1.23-1.82) 4.45E-05 0.48 
rs1950005 6 154481394 A/G 0.5 1 0.7 (0.59-0.83) 4.17E-05 0.48 
rs9383692 6 154471682 G/A 0.53 0.99 0.7 (0.59-0.83) 5.68E-05 0.48 
rs9397689 6 154467342 A/C 0.58 0.98 0.7 (0.59-0.83) 6.54E-05 0.48 
rs9479767 6 154476528 C/T 0.5 1 0.7 (0.59-0.83) 5.23E-05 0.48 
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Table 28. SNPs significantly associated with lung cancer risk among female African 
American lung cancer cases and controls (N=2,353). 
SNP Chr. BP 
Risk/ 
Ref. 
Allele 
Risk 
Allele 
Freq. 
Info 
Score OR 95% CI 
Unadjusted 
P-value 
FDR 
P-value 
rs17486278 15 78867482 C/A 0.3 1 1.51 (1.3-1.76) 1.16E-07 4.29E-03 
rs113931022 15 78901113 T/C 0.18 1 1.57 (1.31-1.88) 1.38E-06 7.53E-03 
rs138544659 15 78900701 G/T 0.18 1 1.57 (1.3-1.88) 1.42E-06 7.53E-03 
rs112878080 15 78900647 G/A 0.18 1 1.57 (1.3-1.88) 1.42E-06 7.53E-03 
rs147144681 15 78900908 T/C 0.18 1 1.58 (1.32-1.9) 1.03E-06 7.53E-03 
rs111704647 15 78900650 T/C 0.18 1 1.56 (1.3-1.88) 1.43E-06 7.53E-03 
rs55676755 15 78898932 G/C 0.17 1 1.59 (1.32-1.92) 9.97E-07 7.53E-03 
rs56077333 15 78899003 A/C 0.18 1 1.55 (1.29-1.86) 2.37E-06 0.01 
rs12914385 15 78898723 T/C 0.2 1 1.51 (1.26-1.8) 5.49E-06 0.02 
rs55781567 15 78857986 G/C 0.28 1 1.42 (1.21-1.66) 1.50E-05 0.06 
rs58365910 15 78849034 C/T 0.27 0.98 1.41 (1.2-1.66) 3.20E-05 0.10 
rs7486184 12 88847001 G/A 0.53 0.98 1.35 (1.17-1.55) 3.33E-05 0.10 
 
 
Table 29. Top SNPs associated with lung cancer risk among male African American lung 
cancer cases and controls (N=1,900). 
SNP Chr. BP 
Risk/ 
Ref. 
Allele 
Risk 
Allele 
Freq. 
Info 
Score OR 95% CI 
Unadjusted 
P-value 
FDR 
P-value 
rs3825845 15 78910258 T/C 0.23 1 0.7 (0.59-0.83) 4.57E-05 0.31 
rs569207 15 78873119 T/C 0.28 1 0.72 (0.62-0.85) 5.73E-05 0.31 
rs576982 15 78870803 T/C 0.29 1 0.72 (0.61-0.84) 3.25E-05 0.31 
rs637137 15 78873976 A/T 0.29 1 0.72 (0.62-0.85) 5.77E-05 0.31 
rs664172 15 78862762 A/G 0.28 1 0.72 (0.61-0.84) 4.24E-05 0.31 
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Table 30. SNPs significantly associated with lung cancer risk among ever smoking African 
American lung cancer cases and controls (N=2,891). 
SNP Chr. BP 
Risk/ 
Ref.  
Allele 
Risk 
Allele 
Freq. 
Info 
Score OR 95% CI 
Unadjusted 
P-value 
FDR 
P-value 
rs17486278 15 78867482 C/A 0.31 1 1.41 (1.26-1.58) 3.84E-09 1.42E-04 
rs55781567 15 78857986 G/C 0.28 1 1.38 (1.22-1.54) 7.01E-08 1.30E-03 
rs147144681 15 78900908 T/C 0.19 1 1.39 (1.22-1.59) 1.60E-06 8.45E-03 
rs2036527 15 78851615 A/G 0.23 1 1.36 (1.2-1.55) 1.24E-06 8.45E-03 
rs576982 15 78870803 T/C 0.28 1 0.75 (0.67-0.84) 1.43E-06 8.45E-03 
rs664172 15 78862762 A/G 0.27 1 0.74 (0.66-0.84) 8.06E-07 8.45E-03 
rs667282 15 78863472 C/T 0.28 1 0.75 (0.66-0.84) 9.47E-07 8.45E-03 
rs11637630 15 78899719 A/G 0.72 0.99 1.32 (1.18-1.49) 2.34E-06 9.94E-03 
rs637137 15 78873976 A/T 0.28 1 0.76 (0.67-0.85) 2.42E-06 9.94E-03 
rs12440014 15 78926726 G/C 0.22 0.9 0.73 (0.64-0.83) 2.75E-06 0.01 
rs3825845 15 78910258 T/C 0.23 0.99 0.74 (0.65-0.84) 3.21E-06 0.01 
rs938682 15 78896547 A/G 0.72 1 1.32 (1.17-1.49) 3.31E-06 0.01 
rs503464 15 78857896 A/T 0.26 0.98 0.76 (0.67-0.85) 5.74E-06 0.01 
rs55676755 15 78898932 G/C 0.18 1 1.37 (1.2-1.57) 5.59E-06 0.01 
rs569207 15 78873119 T/C 0.28 1 0.76 (0.68-0.86) 5.37E-06 0.01 
rs7183604 15 78899213 C/T 0.73 0.99 1.31 (1.17-1.48) 5.84E-06 0.01 
rs58365910 15 78849034 C/T 0.27 0.98 1.32 (1.17-1.49) 6.45E-06 0.01 
rs2456020 15 78868398 T/C 0.39 1 0.78 (0.71-0.87) 9.66E-06 0.02 
rs189218934 15 78903987 C/T 0.73 0.99 1.31 (1.16-1.47) 1.10E-05 0.02 
rs113931022 15 78901113 T/C 0.19 1 1.34 (1.18-1.53) 1.40E-05 0.02 
rs138544659 15 78900701 G/T 0.19 1 1.34 (1.18-1.53) 1.41E-05 0.02 
rs112878080 15 78900647 G/A 0.19 1 1.34 (1.18-1.53) 1.41E-05 0.02 
rs7170068 15 78912943 A/G 0.22 0.99 0.75 (0.66-0.85) 1.25E-05 0.02 
rs111704647 15 78900650 T/C 0.19 1 1.34 (1.17-1.53) 1.71E-05 0.03 
rs56077333 15 78899003 A/C 0.19 1 1.33 (1.17-1.52) 2.34E-05 0.03 
rs2735940 5 1296486 G/A 0.46 0.98 0.8 (0.72-0.89) 3.69E-05 0.05 
rs12914385 15 78898723 T/C 0.21 1 1.31 (1.15-1.49) 4.19E-05 0.06 
rs905739 15 78845110 G/A 0.25 0.98 0.77 (0.68-0.87) 4.13E-05 0.06 
rs2853672 5 1292983 A/C 0.46 1 0.8 (0.72-0.89) 5.06E-05 0.06 
rs2853677 5 1287194 A/G 0.71 1 0.79 (0.7-0.89) 5.88E-05 0.07 
rs7186207 16 72035359 C/T 0.58 1 1.25 (1.12-1.39) 5.76E-05 0.07 
rs951266 15 78878541 A/G 0.12 0.99 1.41 (1.19-1.66) 6.13E-05 0.07 
rs8051239 16 72036257 A/T 0.62 1 1.25 (1.12-1.39) 8.21E-05 0.09 
rs7195958 16 72036577 G/A 0.62 1 1.24 (1.11-1.39) 9.77E-05 0.10 
rs9928425 16 53854498 G/A 0.93 0.99 1.51 (1.23-1.86) 9.77E-05 0.10 
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Table 31. Top SNPs of suggestive significance among never smoking African American 
lung cancer cases and controls (N=1,318). 
SNP Chr. BP 
Risk/ 
Ref. 
Allele 
Risk 
Allele 
Freq. 
Info 
Score OR 95% CI 
Unadjusted 
P-value 
FDR 
P-value 
rs115936429 5 638087 A/G 0.03 0.99 7.19 (3-17.22) 9.67E-06 0.13 
rs200570688 15 78265899 T/C 0.38 0.93 1.99 (1.47-2.7) 1.02E-05 0.13 
rs2937593 5 629879 T/C 0.03 0.96 7.47 (3.12-17.89) 6.50E-06 0.13 
 
Table 32. SNP*sex interaction p-values for SNPs significantly associated with lung cancer 
risk in sex-stratified analyses. 
SNP 
Unadjusted 
P-value 
FDR 
P-value 
rs17486278 1.98E-01 2.37E-01 
rs113931022 5.97E-03 1.43E-02 
rs138544659 5.97E-03 1.43E-02 
rs112878080 5.97E-03 1.43E-02 
rs147144681 1.99E-02 2.66E-02 
rs111704647 5.47E-03 1.43E-02 
rs55676755 9.73E-03 1.57E-02 
rs56077333 7.33E-03 1.47E-02 
rs12914385 1.05E-02 1.57E-02 
rs55781567 5.87E-02 5.87E-01 
rs58365910 2.34E-01 2.55E-01 
rs7486184 8.51E-06 1.02E-04 
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Table 33. SNP*Smoking interaction p-values for SNPs significantly associated with lung 
cancer risk in smoking status-stratified analyses. 
SNP 
Unadjusted 
P-value 
FDR 
P-value 
rs17486278 3.08 E-01 6.23 E-01 
rs55781567 7.74 E-01 8.40 E-01 
rs147144681 2.24 E-01 6.23 E-01 
rs2036527 8.80E-01 9.07E-01 
rs576982 3.40 E-01 6.23 E-01 
rs664172 2.85 E-01 6.23 E-01 
rs667282 3.48 E-01 6.23 E-01 
rs11637630 2.80 E-01 6.23 E-01 
rs637137 3.79 E-01 6.26 E-01 
rs12440014 1.21 E-01 6.23 E-01 
rs3825845 2.72 E-01 6.23 E-01 
rs938682 5.50 E-01 7.44 E-01 
rs503464 3.48E-01 6.23E-01 
rs55676755 2.96 E-01 6.23 E-01 
rs569207 6.06 E-01 7.69 E-01 
rs7183604 5.39 E-01 7.44 E-01 
rs58365910 3.59E-01 6.23E-01 
rs2456020 6.47 E-01 7.91 E-01 
rs189218934 4.53 E-01 7.12 E-01 
rs113931022 2.12 E-01 6.23 E-01 
rs138544659 2.12 E-01 6.23 E-01 
rs112878080 2.12 E-01 6.23 E-01 
rs7170068 1.86 E-01 6.23 E-01 
rs111704647 2.18 E-01 6.23 E-01 
rs56077333 2.47 E-01 6.23 E-01 
rs2735940 7.89E-01 8.40E-01 
rs12914385 3.41 E-01 6.23 E-01 
rs905739 3.38E-01 6.23E-01 
rs2853672 7.89E-01 8.40E-01 
rs2853677 7.38E-01 8.40E-01 
rs7186207 9.92 E-01 9.92 E-01 
rs951266 5.63 E-01 7.44 E-01 
rs8051239 5.52 E-01 7.44 E-01 
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Figure 27. Quality control of African American lung cancer cases and controls genotyped 
on the Illumina Human Hap 1M Duo array. 
 
  
African American Lung Cancer  
Cases and Controls 
N=4446 individuals 
N=1,124,592 SNPs 
N=4253 individuals 
N=1,124,592 SNPs 
Final QC Dataset 
N=4,253 individuals 
N= 982,629 SNPs 
Sample QC 
Sex Check: N=0 
<95% Genotyping Efficiency: N=46 
Related Individuals: N=147 
SNP QC 
Non-autosomal: N=39,940 
<1% Minor Allele Frequency: N=76,558 
<95% Genotyping Efficiency: N=17,856 
Hardy-Weinberg Equilibrium p<0.0000001: N=7,609 
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Figure 28. Overlap between the number of SNPs in LD with a reported SNP in the MXL, 
CEU, CHB, and YRI 1000 Genomes reference populations for variants previously reported 
in Latin populations. 
MXL= Mexican ancestry from Los Angeles, CA; CEU=Utah residents (CEPH) with Northern an 
Western European ancestry; CHB=Han Chinese in Beijing, China; YRI=Yoruba in Ibadan, 
Nigeria 
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Figure 29. Overlap between the number of SNPs in LD with a reported SNP in the ASW, 
YRI, and CEU 1000 Genomes reference populations for variants previously reported in 
African-descent populations. 
ASW=Americans of African ancestry in SW USA; CEU=Utah residents (CEPH) with Northern 
an Western European ancestry; YRI=Yoruba in Ibadan, Nigeria 
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Figure 30. Logistic regression results for pleiotropic genetic associations with lung cancer 
risk among all African American lung cancer cases (N=4,253). 
Red line = 10% false discover rate (FDR); blue line = 5% FDR. 
!
Figure 31. Meta-analysis logistic regression results for pleiotropic genetic associations with 
lung cancer risk 
Red line = 10% false discover rate (FDR); blue line = 5% FDR. !
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Figure 32. Logistic regression results for pleiotropic genetic associations with lung cancer 
risk among African American adenocarcinoma cases and controls (N=3,475). 
Red line = 10% FDR; blue line = 5% FDR. 
 
!
Figure 33. Logistic regression results for pleiotropic genetic associations with lung cancer 
risk among African American squamous cell carcinoma cases and controls (N=3,180). 
Red line = 10% FDR; blue line = 5% FDR. 
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Figure 34. Logistic regression results for pleiotropic genetic associations with lung cancer 
risk among African American female cases and controls (N=2,353). 
Red line = 10% FDR; blue line = 5% FDR. 
!
Figure 35. Logistic regression results for pleiotropic genetic associations with lung cancer 
risk among African American male cases and controls (N=1,900). 
Red line = 10% FDR; blue line = 5% FDR. 
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Figure 36. Logistic regression results for pleiotropic genetic associations with lung cancer 
risk among African American ever smoking cases and controls (N=2,891). 
Red line = 10% FDR; blue line = 5% FDR. 
!
Figure 37. Logistic regression results for pleiotropic genetic associations with lung cancer 
risk among African American never smoking cases and controls (N=1,318). 
Red line = 10% FDR; blue line = 5% FDR. 
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Figure 38. Chromosome 16q22.2 as visualized in the UCSC Genome Browser. 
Variants rs7186207, rs8051239, rs7195958, and rs3213422 are denoted by faint yellow lines and labeled in black under the “NHGRI-
EBI Catalog of Published Genome-Wide Association Studies” track. 
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Figure 39. Power of the present study to detect associations at various allele frequencies 
and effect sizes. 
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CHAPTER 5 
 
CONCLUSION AND FUTURE DIRECTIONS 
 
 The goal of this dissertation was to examine genetic contributors to lung cancer survival 
and risk in African Americans. The three aims were as follows: 
1. Examine the role of African genetic ancestry compared to other known contributors 
to lung cancer survival in a population of whites and blacks (Chapter 2). 
2. Examine variants previously associated with lung cancer survival and identify novel 
common and rare variants associated with lung cancer survival in an African 
American population (Chapter 3). 
3. Investigate cross-cancer pleiotropic associations for lung cancer risk in African 
Americans (Chapter 4).  
Our analysis of lung cancer survival utilized individuals from the Southern Community 
Cohort Study (SCCS), a prospective study of ~86,000 individuals recruited in the Southeastern 
Untied States. The SCCS is a unique study population in that the majority of individuals are 
black/African American. Furthermore, the primary method of recruitment was through 
community health centers, resulting in a low-income population with relatively equal access to 
healthcare (though exceptions exist for the ~15% of individuals recruited from the general 
population) (Signorello et al. 2005, Signorello et al. 2010). Using a population of white and 
black/African American incident lung cancer cases from the SCCS, we sought to provide a better 
understanding of the impact of genetic ancestry on lung cancer survival, while adjusting for 
known clinical, environmental, and socioeconomic confounders. We find that global African 
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ancestry is not associated with lung cancer survival, nor does it increase accuracy of lung cancer 
survival prediction models. In contrast, we find that stage at diagnosis and the type of treatment 
received are highly predictive of lung cancer survival.  
This study contributes evidence against a racial disparity in lung cancer survival due to 
genetics alone and instead suggests that the observed reduced survival time in blacks compared 
to whites is the result of differing stage and treatment distributions. Even in our study population 
of relatively equal access to healthcare, we observe that stage at diagnosis and treatment received 
differ between blacks and whites. Additionally, stage and treatment distributions vary 
dramatically between the SCCS discovery population and WSU replication population from the 
Metropolitan Detroit area. Future research should focus on providing a better understanding of 
the interplay between stage, treatment, and race/ancestry in lung cancer survival. Clinically, 
emphasis should be placed on shifting the stage distribution toward earlier stage diagnoses for all 
races, which will naturally increase lung cancer survival rates. Increasing the frequency of early 
stage diagnoses could result from increased lung cancer screening efforts among all racial/ethnic 
groups. Furthermore, increased knowledge of known risk factors will also improve our ability to 
detect and diagnose lung cancer at earlier stages.  
The second aim of this dissertation sought to identify genetic variants associated with 
lung cancer survival in the same population of African Americans from the SCCS used in Aim 1. 
Our primary analysis focused first on replicating variants previously associated with lung cancer 
survival, then on identifying novel common and rare variation associated with lung cancer 
survival. Our primary analysis identified one SNP, rs1878022 on chromosome 12q23.3, 
associated with lung cancer survival, though the direction of effect was in contrast to previous 
literature in a European population (Wu et al. 2011), suggesting possible population-specific 
! 135 
effects. Continued research is required to confirm this association and its opposing effects in 
European- vs. African-descent populations. Fine-mapping of this region is also necessary to 
identify the causal allele and understand the functional impact of variation and its effect on lung 
cancer survival.  
While we examined rare variant associations through multiple aggregation-based 
methods, we are underpowered to draw any conclusions about their association with lung cancer 
survival. Substantially increased sample sizes are required in order to confirm any associations 
suggested in the present analysis. Our analysis of common variants, on the other hand, identified 
several variants with suggestive significance, including a peak on chromosome 6p21.33. While 
previous literature on this region provides biological plausibility (Sasaki et al. 2007, Tompkins et 
al. 2009, Yang et al. 2010, Xun et al. 2011, Wu et al. 2013), we lacked an appropriate replication 
population to confirm the association. Thus, replication remains necessary. Combined with the 
primary analysis of Aim 2, we identified multiple gene regions that may be associated with lung 
cancer survival. Should these regions be confirmed through replication, future analysis should 
focus on understanding the mechanism through which they influence survival and their potential 
as therapeutic targets in lung cancer treatment. 
Finally, the third aim of this dissertation sought to identify genetic variants associated 
with lung cancer risk. Using a large population of African American lung cancer case and 
controls from five different study populations, we identified several genetic loci associated with 
lung cancer risk, including previous associations on chromosomes 15q25 and 5p15. Significant 
peaks on chromosomes 5q14.3, 16q22.2, and 17q12 were observed among all individuals and a 
SNP on 12q21.32 fell just below our significance threshold. SNPs in all of these regions have 
been previously implicated in cancer risk, suggesting plausibility for a role in lung cancer. 
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However, no replication population was available to confirm these novel associations. Future 
analysis requires replicating significant associations and investigating LD structure for the 
purpose of identifying causal alleles conferring increased lung cancer risk. Positive identification 
of lung cancer risk alleles has the potential to increase prevention and detection methods, though 
such applications would require extensive continued epidemiologic and molecular research.  
The final aim also provided evidence of the utility in using pleiotropy to perform 
hypothesis-driven research. Unlike traditional genome-wide association studies, we only 
examined SNPs with a priori evidence for an association with cancer risk, reducing the total 
number of tests performed. Because we were not hindered by a high multiple testing correction, 
we were able to detect novel lung cancer risk loci, likely rejected as false positives in previous 
studies. Furthermore, our study shows the importance of considering population structure 
differences across races: none of our most significant associations were among the list of SNPs 
reported in the NHGRI-EBI GWAS catalog, but were examined because of their strong 
correlation to a reported SNP. Future studies of pleiotropy should include such considerations. 
Taken together, the aims of this dissertation expand our understanding of the genetic 
components of lung cancer survival and risk in African Americans. While survival and risk are 
often considered separately, the high frequency of late stage diagnoses combined with extremely 
poor survival rates for such diagnoses makes knowledge of lung cancer risk factors also an 
important part of the fight to increase lung cancer survival rates. Only by understanding the 
social, environmental, and genetic risk factors and their combined impact, will we be able to 
fully address the observed racial disparity in lung cancer incidence and survival.   
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